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1. Introduction 
 
1.1 Background    
The view of the bronchoscopist is limited to the lumen and the internal surface of 
the airways. Intramural or extraluminary pathological changes can only be 
suspected from indirect signs of tumor, such as discoloration and swelling of the 
mucosa, hyper-vascularization, leveling of the superficial cartilagenous relief, or 
impression, displacement, or disruption of airway wall architecture. As especially 
in malignancies, assessment beyond the endoscopically visible may be crucial for 
the fate of the patient, thus there is a definite need to extend the bronchoscopist’s 
view beyond the confinement of the tracheobronchial wall (32).   
Radiological diagnostic procedures such as computed tomography scan and 
magnetic resonance imaging have certain shortcomings in mediastinal staging of 
lung cancer (12, 44, 45).  An example is the exact detailed structure of the 
tracheobronchial wall; subsequently the depth of tumor invasion is often difficult or 
impossible to define precisely. Hence there is need to improve diagnostic 
procedures in this setting (82).  
Ultrasound has gained wide acceptance as a standard diagnostic imaging technique 
(73). The introduction of real–time systems and improved resolution of the 
electronically focused phased array transducers have made US competitive in some 
situations with chest X-ray, fluoroscopy, and CT scan (47). 
Small flexible catheter-based transducer -miniature transducers- originally designed 
for intravascular ultrasonographic applications, have been used in conjunction with 
flexible endoscopy of the genitourinary and gastrointestinal tracts because of their 
ability to produce images beyond the luminal surface, providing information about 
the exact location of masses as well as such normal structures as arteries, veins and 
lymph nodes (27). 
Endosonography is now an established technique evaluating lesions adjacent to or 
arising from the wall of the upper gastrointestinal organs (23). 
In the respiratory tract the technical problems of endobronchial ultrasound are 
much more complex compared to other organs, primarily because air present in the 
tracheobronchial lumen and lung parenchyma interfering with penetration of the 
ultrasound signal. Its use in topical anesthesia is further complicated by respiratory 
movements, cough, tip displacement, etc.. For these reasons, the technique could 
not be established for a long time (10).  
The use of a catheter-based miniaturized ultrasound transducer for the study of the 
tracheobronchial tree as part of a fiberoptic bronchoscopic examination was first 
described by Hürter and Hanrath of Aachen, Germany in 1990 (38), followed by 
Becker of Heidelberg, who published preliminary reports in 1994, after Olympus 
introduced significant technical improvements to devices in use (5). 
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Becker’s work was presaged by early Japanese reports in EBUS from Ono and his 
colleagues in 1993 and 1994 (58, 59), followed by several publications and 
significant technical advances (41, 42, 66). 
Goldberg and his colleagues evaluated the role of endoluminal ultrasound guidance 
for diagnosis during routine FFB for patients with known or suspected pulmonary 
neoplasm. The result of this first American study was published in 1994 (27). 
Endobronchial ultrasound was introduced into clinical hospital practice in 2000, as 
a new diagnostic procedure visualizing bronchial and peribronchial tumors, 
mediastinal lymph nodes and adjacent vascular structures, with the aim of assessing 
bronchial wall and extraluminal pathology. Since major European publications deal 
with EBUS application in general anesthesia (8, 19, 36), its use in routine 
bronchoscopy in topical anesthesia needs to be evaluated more closely.  
 
1.2 Principles of ultrasonography 
 
1.2.1 Principles of wave length 
Imaging by ultrasound depends on differences in transmission, absorption, 
scattering and reflection of ultrasonic waves by tissues of different impedance. 
Frequencies beyond the hearing range of more than 20,000 Hz are defined as 
ultrasonic waves. In medical application, frequencies in the MHz range are used for 
creating images.  
The frequency is the number of oscillations per unit of time, expressed in the unit 
of Hz. An increase in frequency means a decrease in the wave length. The medical 
diagnostic ultrasound waves have frequencies between 2 and 20 MHz (30 MHz is 
still being investigated) and wave lengths from 0.8 to 0.15 mm (10). 
 
1.2.2 Principles of ultrasound imaging 
Ultrasound is attenuated when it travels through a medium, and the attenuation rate 
increases as the frequency increases. Since ultrasound cannot penetrate the air due 
to the high attenuation ratio, it is necessary to fill the space between an ultrasound 
transducer and observation subject with a medium such as water. The ultrasound 
transducer produces an ultrasound image by converting electrical and ultrasound 
signals based on the principles that the ultrasound is partially transmitted and 
partially reflected at the boundary of the medium (43). 
 
 
 
 
 
 
 
                                   
                                                                                                                                                                    
                                                                                                                     3 
 
Figure 1: Principles how ultrasound image is made (43) 
 
 
 
In non-technical terms, the intensity of the received waves is transformed into 
brightness (echogenicity or echodensity) on a black and white screen and the time 
elapsed from sending to reception is depicted as distance from the ultrasonic probe. 
Water has very low resistance and ultrasound waves travel with high speed, 
whereas air and bony structures are almost impenetrable and reflect the 
ultrasonographic waves almost completely. The processor is set to the speed of 
1.540 meter/second in average water containing tissue of 37 °C as standard for its 
calculation. Differences from this standard are shown as brightness or darkness. 
Thus, if a tissue contains a lot of water, the sound waves travel faster and it appears 
darker. The effect of deeper penetration through fluid is called enhancement. The 
opposite effect is complete reflection by impenetrable tissues, which causes a 
shadow behind the obstacle (10). 
The ultrasonic image does not strictly reflect anatomic structure but is a composite 
of reflection attenuation, dispersion, thermal transformation, etc., that are 
dependent on the specific properties of different tissues with respect to the 
individual impendence (10). 
 
1.2.3 Factors influencing the quality of ultrasound image 
Three major factors influence the quality of the ultrasonic image: contact of the 
ultrasonic probe with the tissue, depth of penetration of the ultrasonic wave and 
spatial resolution of the different structures (32).  
The lower the frequency of the ultrasonic wave, the higher the depth of penetration 
and vice versa; the higher the frequency, the higher the resolution of structures. 
These technical implementations have to be taken into account when applying 
ultrasound for diagnostic purposes and in interpretation of ultrasonic images (10). 
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1.3 Ultrasound device 
Different systems have been tested in vitro, a Japanese group applied special 
ultrasonic bronchofiberscopes that have a curvilinear scanner with 7.5 MHz at one 
side of the tip. The image was of comparatively low resolution and showed a very 
limited sector of the peribronchial structures. The maximum diameter of these 
devices is 6.3 mm (58, 59). For 360° imaging of the mediastinal structures, the 
instrument has to be rotated around its axis during the procedure, and the different 
planes have to be reconstructed like CT images. As by this procedure a direct 
coherent circular image of the mediastinal structures could not be produced, a dif-
ferent solution by applying miniaturized probes that are used for endoscopic and 
cardiovascular endosonography was tried (32). 
The initial miniaturized Olympus probes operated with 7.5 MHz. Later, probes of 
12 and 20 MHz became available (UM-2R/3R, driving unit MH-240 and processor 
EU-M 20 and 30; The first probe had a diameter of 3 mm, and the mechanical 
signal transducer at the tip was rotating at approximately 400 rpm and produced a 
360° image perpendicular to its axis. Because of its large diameter, it was mainly 
applied during rigid bronchoscopy using a metallic tube as guide. Later, models of 
12 and 20 MHz with a diameter of 2.5 mm could be introduced via biopsy channels 
of at least 2.8 mm through the flexible fiberoscopes (10). 
Endovascular ultrasonic probes (CVIS, Sonotron Company Milwaukee, USA) had 
been already used in ultrasonic investigation of the pulmonary artery. These probes 
have an outer diameter of 10 F (12 MHz) and 8 F (20 MHz). The axial resolution is 
0.12 mm and the radial resolution 0.23 mm. Rotation of this mechanical transducer 
is 600 rpm. Therefore, it produces less motion artifacts than the early Olympus 
probes. The ultrasonic wave is reflected from the transducer by a mirror with an 
30° angulation of its surface. Thus, the ultrasonic image is slightly tilted forward 
from the tip of the ultrasonic probe (10).   
 
1.4 Technique of endobronchial ultrasound 
EBUS is applied under either general anesthesia using rigid bronchoscopy or local 
anesthesia with oxygen supplementation and sedation using a fiberoptic 
bronchoscope (10, 19, 39, 69).   
The main problem of application inside the airways is coupling of the ultrasonic 
probe to the tracheobronchial wall. Lobar and smaller peripheral bronchi present no 
significant problems in this respect, but due to the surrounding air and the relatively 
rigid cartilaginous wall, this is impossible in the central airways. In these, with the 
naked probe one gets only a very limited sectorial view. This is why a flexible 
introducer catheter equipped with a balloon at the tip (MH-246R) was developed 
for the Olympus probes. Once this balloon is filled with water, it completely fills 
the airway and provides a complete 360° view of the mediastinal structures. The 
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water simultaneously serves as enhancing medium for the ultrasonic waves. Thus, 
under favorable conditions, the depth of penetration even for the 20 MHz waves 
may be up to 5 cm. Because of their higher resolution, these probes now are 
preferable to the 7.5 and 12-MHz probes. So far, it is not possible yet to equip the 
CVIS catheter with a similar device. Thus, their use is restricted to the peripheral 
airways and to the lung tissue (10). 
Since the first balloon catheters had a diameter of 3.5 mm, they could not be 
introduced through the biopsy channel of ordinary bronchoscopes. They had to be 
applied through rigid bronchoscopes, parallel to an ordinary flexible fiberscope or 
via a new flexible Olympus bronchofiberscope with an outer diameter of 7 mm 
(Olympus BF-ST 30). The biopsy channel of the latter instruments is large enough 
to allow the probe to be passed. Nowadays the slimmer diameters US probe (UM-
BS 2O-26R) with balloon catheter are available which can be introduced through 
the biopsy channel of 2.8 diameter of routine fiberoscopes together with the balloon 
sheath (MAJ-643R) (10). 
Once the probe is placed inside the airways under visual control, the balloon is 
filled until close contact to the wall is established. This can be achieved without 
any problems peripherally and in the main bronchus as long the contralateral lung 
is ventilated. EBUS in the trachea or in a main bronchus after contralateral 
pneumonectomy causes complete occlusion of the airway. Under local anesthesia 
this can be tolerated for very short periods only under sufficient sedation and after 
careful preoxygenation (preferably via an orotracheal tube) (10). General 
anesthesia allows up to 3-4 minutes of apnea for investigation of the mediastinal 
structures (21).  Although some argue that this procedure is justified with respect to 
the useful additional information that can be obtained (10), others make the point 
that flexible bronchoscopy looses much appeal if its use would require general 
anesthesia. (Personal communication, J.A. Nakhosteen).    
 
1.5 Imaging artifacts 
Artifacts can occur due to the following mechanisms: 
a) Slow imaging processing 
 The comparatively slow rotation speed and imaging processing by US compared to 
the respiratory movements and pulsations cause the contours of any structure to 
move when the US beam reaches the same position after one full rotation cycle, 
leading to an edge between the images. Thus, the contours of the structure appear 
to have multiple edges or artificial elongation (comet-like extension) (7,10).  
b) Insufficient contact 
 The insufficient contact between the balloon and the bronchial wall leads to 
multiple repeated reflections of the balloon echo. This is the most frequent artifact 
resulting from reflections at the inner surface of the balloon. It may vary with the 
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material. Obviously, not all types of latex are equally penetrable for the ultrasonic 
wave (7, 10). 
c) Interference 
 The interference of the video signal of the video endoscopes leads to a radiation 
corona overlying the US image (7, 10). 
d) Air bubbles 
 Air inside the fluid filled balloon leads to bright reflexes and the balloon is 
elongated (rabbit ear shape) (7, 10). 
d) Irregularly rotating US probe 
 Friction of the tip of the US probe inside the balloon sheath causes multiple 
indentations of image structures (10). 
The artifacts are not synchronous with the physiological movements, they are 
easily recognized, and after some time of accommodation, no longer interfere with 
the diagnostic process. 
As the central airways are surrounded by strongly reflecting structures like lung 
tissue, vertebral column, calcified cartilages or lymph nodes, artifacts may also 
occur due to these strong reflections. Frequently, lymph nodes may show distorted 
triangular contours at the far side. Depending on their echogencity, the distal 
contours may be blurred. This is also true for the left atrium and the pulmonary 
vein. Detailed analysis of chambers of the heart and its valves however is not 
possible because of the limited range of the 20 MHz probe (7, 10). 
 
1.6 Sonographic anatomy                          
 
1.6.1 The tracheobronchial wall and lung parenchyma 
The tracheobronchial wall is highly echogenic and has a peculiar ultrasonographic 
laminar structure (79). 
 
1.6.1.1 Laminar structure of the tracheobronchial wall 
Since the extent of bronchial wall involvement in extraluminal and early lung 
cancer pathology is of major concern in endobronchial staging, the exact definition 
of mucosal layers has been a major focus of attention in EBUS studies. 
In the digestive system, it has been demonstrated that the wall is depicted as a 
laminal structure with EUS. The anatomical structures corresponding to each echo 
layer have been defined. However, anatomical structures corresponding to each 
laminar EBUS layer have not been fully determined yet (82).    
Hürter and Hanrath reported that the bronchial wall has unilaminar and trilaminar 
structures next to one another corresponding to membranous and cartilaginous parts 
of the bronchial wall (39). 
Steiner and coworkers (79), using either 12.5 or 20 MHz ultrasonic probes reported 
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that the normal bronchial wall appeared as three echo layers. They were interpreted 
as hyperechogenic mucosa, hypoechogenic muscularis, and hyperechogenic 
adventitia.  
Using 20 MHz ultrasonic probes, others reported that the tracheobronchial wall was 
represented as a 7-layer sonographic structure of the central airways. The mucosa 
on the inner surface shows a very bright echo that is further enhanced by the 
adjacent balloon. The submucosa is comparatively echo poor and clearly 
distinguishes the mucosa from the supporting structures of the tracheobronchial 
wall. The internal structures of the cartilage itself and of the intercartilagenous 
connective tissue are equally echo poor and cannot be differentiated from each 
other. But the strong echo of the endochondrium and of the perichondrium can 
always be seen in the intact structure. The adjacent external sonographic double 
layer structures of the supporting connective tissue and of the adventitia are easily 
missed under low power magnification due to the bright reflex of the 
perichondrium.  However, no histological evidence of these hypotheses was 
demonstrated (10). 
On the other hand Kurimoto and co-workers (42) identified the laminar structure 
comparing images of normal bronchial structure obtained by EBUS and histo-
pathological tissue by conducting Needle-puncture experiment, demonstrating the 
histological anatomical structures corresponding to each layer using 20 MHZ 
ultrasound probes. They reported that the cartilaginous portion of extrapulmonary 
bronchi and the intrapulmonary bronchi is depicted as a 5-layer structure and that 
the membranous portion of the extrapulmonary bronchi appears as 3-layer 
structure. The fourth layer (hypoechoic), which represents the cartilage of the 
cartilaginous portion of the extrapulmonary bronchi and the intrapulmonary 
bronchi, and the second layer (hypoechoic), which represents the smooth muscle of 
the membranous portion, can often be clearly pointed out. These layers are 
considered to be the key to correct determination of depth of tumor invasion. 
 
A precondition for obtaining the precise laminar structure by ultrasound is in 
positioning the probe at the center of the lumen so that the ultrasound enters the 
bronchial wall at right angles. This is confirmed when the first layer is a 
hyperechoic, not hypoechoic marginal echo (42). 
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Table 1: Transbronchial ultrasound imaging of tracheobronchial wall and its   
               corresponding structures (42, 82). 
 Ultrasound 
imaging 
(20MHz) 
 
Layer 
Ultrasound 
imaging 
(20MHz) 
 
Echo-
intensity 
Corresponding anatomical     
 structures 
Cartilagenous 
Portion 
First 
(inner) 
 
  
Second 
 
Third 
 
 
 
Fourth 
 
Fifth 
(outer) 
Hyper 
 
 
 
Hypo 
 
Hyper 
 
 
 
Hypo 
 
Hyper 
Marginal echo containing the 
mucous epithelium and some inner 
part of the submucosal tissue. 
 
Submucosal tissue. 
 
Marginal echo (inner-side border of 
the cartilage) containing some 
inner part of the cartilage. 
 
Cartilage. 
 
Marginal echo (outer-side border of 
the cartilage) containing the 
adventitia.  
 
Membranous 
Portion 
 
First 
(inner) 
 
 
Second 
 
 
Third 
(outer) 
 
Hyper 
 
 
 
Hypo 
 
 
Hyper 
 
Marginal echo containing the 
mucous epithelium and some inner 
part of the submucosal tissue. 
 
Submucosal tissue. (Smooth 
muscle) 
 
Marginal echo (outer-side border of 
the submucosal tissue) containing 
the adventitia.  
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Figure 2: EBUS layers of tracheobronchial wall (43) 
 
 
 
 
 
 
 
 
 
 
 
 
     
      a)         b) 
 
a) EBUS-layers of tracheal wall, anteriorly the cartilaginous portion (5 layers), posteriorly 
the membranous portion (3 layers).    
b) Layers of the cartilaginous portion of the bronchial wall (5 layers) by EBUS.  
 
1.6.1.2 Lung parenchyma 
The normal lung parenchyma is characterized by a dense pattern of reflections 
(highly echogenic) due to the multiple air/soft-tissue interfaces found in normal 
lung (79). 
Masses in the periphery or central portions of the lungs contain different echo 
texture than surrounding normal lung. Bronchial carcinoma of all histological types 
has an echo poor texture i.e. less echogenicity both in vivo and in vitro, than 
surrounding tissue. This can easily be differentiated from the highly echogenic 
normal bronchial wall and lung parenchyma. 
Endobronchial sonography identifies endobronchial and peribronchial tumor 
growth as well as infiltration of the bronchial wall. In some patients, however, the 
echotexture is complex reflecting areas of increased echogenicity believed to 
represent areas of necrosis and hemorrhage (27, 39). 
 
1.6.2 Mediastinum 
 
1.6.2.1 Orientation in the mediastinum  
Orientation within the mediastinum is difficult (15). Besides the complex anatomy 
of the mediastinal structures and motion artifacts by respiration and pulsation, this 
is mainly due to the frequently unusual plains of the sonographic image, 
predetermined by the airway angles. Inside the trachea, the ultrasonic image equals 
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the horizontal plane represented by CT scanning of the mediastinum. Passing into 
the main bronchi, the image continuously tilts towards a more sagittal plane, 
especially in the left main bronchus. In the peripheral part of the upper lobe 
bronchi, an inverse horizontal plane is reached (10).  
 
1.6.2.2 Nodal anatomy 
Lymph nodes appear denser; a hyperechogenic center can be recognized in some 
cases representing the reflective fatty hilus of the node (79). This typical pattern 
suggests normality and has been identified in nodes in other areas of the body (30). 
The nodal anatomy can be elicited from figure 3. 
 
1.6.2.3 Other mediastinal structures 
The esophagus appears as an oval-shaped multi-layer structure dorsally to the 
trachea, main carinal bifurcation and the left main bronchus. The esophagus is a 
distinct landmark for orientation.  
The vessels are easily recognized by their low echo and pulsation (79).  
 
To understand EBUS, it is necessary to understand the positional relationship 
between the organs around the bronchi. 
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Figure 3: Regional lymph node stations for lung cancer staging (51) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   N2 Nodes = 1-9                                 N2 Nodes = 10-14 
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1.7 Clinical applications of EBUS 
 
1.7.1 Staging of Bronchial carcinoma 
 
1.7.1.1 Primary tumor (T) 
a) Determination of depth of tumor invasion of the tracheobronchial wall 
In every case of macroscopic alteration of the mucosa, concomitant alterations in 
the sonographic structure were found. In many instances, even if the mucosa 
seemed to be intact macroscopically, submucosal tumor spreading was found by 
endobronchial ultrasound. In some instances, it could be followed extending 
beyond the bronchial wall into the parabronchial structures (32). 
Early published reports comparing the depth of invasion in ultrasonograms with 
histopathological findings suggest that EBUS can be a useful diagnostic tool in 
evaluation of tumor invasion to the tracheobronchial wall (41, 42, 82).  
Early Carcinoma: Frequently, tumors that are not visible by high-resolution CT 
scan are defined as early carcinoma. The patho-anatomical definition of early 
cancer is lack of infiltration beyond the submucosa (11).  
EBUS is supposed to improve the prediction for suspicious lesions of 
autofluoresence or white-light-bronchoscopy. The additional information on the 
bronchial wall and the surrounding structures may play a role in early carcinoma 
detection if these observations – at present speculative - are confirmed (33). 
b) Intraluminal Extension 
Herth and Becker reported, that in advanced bronchial carcinoma endoluminal 
ultrasound provides valuable information for therapeutic decisions. In complete 
airway obstruction, they were able to differentiate the basis and the surface of the 
tumor. By passing the stenosis, they could assess patency of the distal airways. This 
information was of importance for endobronchial desobliteration, especially if the 
pulmonary artery was not simultaneously occluded (32). 
c) Peripheral pulmonary lesions 
?Localization: 
EBUS is helpful in localizing and guiding the biopsy of peripheral lesions (27, 41). 
Lesions behind mediastinum and diaphragm, small lesions, low attenuation lesions 
and lesions behind another shadow may all be better visualized by EBUS (41). 
?Qualitative diagnosis: 
Kurimoto and his colleagues reported that opposed to benign masses a malignant 
pattern has no bronchioles, no vessels and heterogenous echogenicity in the tumor 
(41). 
It is also claimed that by analyzing the spectrum of US signals, it might be possible 
to predict the histology of peripheral lesions (57). 
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d) Infiltration of Mediastinal Structures: (regional involvement) 
Even more important in preoperative staging is the diagnosis of infiltration of the 
organs in the mediastinum such as the aorta, vena cava or the main pulmonary 
artery. By radiological methods, this frequently proves difficult. EBUS could dem-
onstrate direct infiltration of the esophageal wall by US of the left main bronchus 
or the distal trachea. EBUS proved to be extremely valuable in diagnosis of 
infiltration of the esophagus by bronchogenic carcinoma. 
Intratracheal ultrasound was especially helpful in diagnosing external infiltration of 
the tracheal wall by tumors of the mediastinal surface of the lung or by primary 
mediastinal tumors. Here, EBUS proved to be superior to radiological examination 
(34). 
  
1.7.1.2 Involvement of lymph nodes (N)        
Lymph node localization and enlargement is easily detected by EBUS, lymph 
nodes down to a size of 2-3 mm can be visualized (11, 39, 69, 79). In a limited 
prospective in vitro study it was not possible to find reliable criteria for the 
malignant infiltration, neither with regard to the echogeneity nor to homogeneity of 
the internal structure or with respect to boundary to the surrounding structures (10). 
This is in contrast to other localizations, for example in E.N.T tumors (31, 48). 
?EBUS assisted Transbronchial Aspiration Needle of mediastinal adenopathy: 
As with the Olympus system simultaneous visual control of the biopsy needle is 
very limited, echography mainly serves for localization of the lymph nodes. TBNA 
is performed sequentially after prior sonographic localization. This is easy as the 
cartilages and airway branches allow exact anatomical localization and guidance of 
the subsequent needle aspiration biopsy (10). 
The addition of endobronchial ultrasound for improvement of these procedures has 
been investigated. Preliminary results showed that it might reduce the number of  
attempts, improve results and increase the diagnostic yield. It was useful in 
sampling small lymph nodes down to 3 mm, and provided lower complication rate 
and further safety by on site visualization of blood vessels preventing inadvertent 
puncture (10, 19, 75). 
 
1.7.2 Mediastinal masses 
Mediastinal masses can be visualized by EBUS and subsequently approached by 
transbronchial/transtracheal needle biopsy if they are localized in close proximity 
to the central airways or if some fluid-containing structure provides an acoustic 
window. Primary mediastinal or bronchogenic cysts in close contact to the airways 
are easily differentiated from solid tumors by their echo-poor internal structure that 
is frequently septated. With solid masses, endosonography is superior to 
radiological procedures in differentiation of compression and infiltration of the wall 
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of the airways. This applies for example to goiter and thyroid carcinoma. In tumors 
of the mediastinum, which are usually localized ventrally to the trachea and the left 
main bronchus, access via the apical segment of the left upper lobe is preferable 
due to its close anatomical relation (10). 
  
1.7.3 Large intrathoracic vessels 
The large intrathoracic vessels adjacent to the central airways can be recognized 
due to their low echo structure and their pulsation. The importance of sonographic 
diagnosis in direct tumor invasion has been discussed above. 
Especially in early infancy and childhood, compression of the airways by vascular 
anomalies is comparatively frequent. EBUS detected such anomalies, even if 
extensive previous cardiovascular diagnostic procedures did not show the 
pathology. Thus, in the future EBUS might be a standard procedure in the diagnosis 
of pediatric malformations. This applies also to extensive thoracic deformities 
where compression of the airways by deviation of the heart, the large intrathoracic 
blood vessels and the thoracic wall can be diagnosed by EBUS preventing more 
invasive radiological procedures like angiography (10). 
 
1.7.4 Pleural Space 
If an atelectasis or pleural effusion provides an acoustic window, the pleural 
surface and mediastinal structures may be visualized. Thus, solid formations of the 
visceral and mediastinal pleura or on the pericardium can be seen (10). 
 
1.7.5 Endobronchial ultrasound in interventional bronchoscopy 
In exploration of central airway stenosis, sonography was useful in assessment of 
its extent and cause in order to choose the best method for interventional 
procedures, i.e. dilatation, laser or stent implantation as well as control of the 
therapeutic effect. In bronchoscopic treatment of malignant tumors with curative 
intent such as photodynamic therapy and endoluminal high-dose radiation, it is 
important that the lesion is not extending beyond the bronchial wall. Here, 
endobronchial sonography proved superior to all other diagnostic procedures, 
according to some authors (32). 
In bronchoscopic palliative brachytherapy of malignant tracheobronchial tumors, 
EBUS determined the extent to which the lesion had affected the bronchial wall, 
thus was helpful in choosing the appropriate dose of irradiation suitable for the 
extent of the lesion, follow up and evaluation of the treatment response (58).   
Correct endoscopic judgment of the healing process of an anastomosis after a 
so-called bronchoplastic surgical procedures (sleeve resection) can be  
problematic. Thus, it is sometimes difficult to differentiate superficial necrosis  
with mucosal swelling and fibrin deposition from imminent dehiscence.  
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Endobronchial ultrasound proved to be very useful in assessment of the 
surrounding structures (6). 
 
1.8 Patient Tolerance 
The procedure is well tolerated by the majority of the patients. Up till now, no 
serious side effects were recorded (19, 27, 39, 69, 70, 75, 82). 
Cough and hypoxemia were reported by Scherer (69, 70) and Falcone (19) in a 
limited group of patients.    
a-Coughing: coughing interferes with the US examination, rendering coupling of 
the probe with the bronchial wall difficult (69). 
b-Hypoxemia: oxygen desaturation can occur in main bronchi or trachea, 
intermittent balloon inflation in the main bronchi was usually tolerated without 
desaturation below 90%. Hypoxemia per se never prevented collection of 
information (69). 
 
1.9 EBUS learning curve:  
The acquisition of good quality images and their interpretation is to a large extent 
dependent on the experience and the skill of the bronchoscopist. With increasing 
number of examinations, the information obtained by the ultrasound images 
increases rapidly with a steep learning curve in few months.  
Familiarization with the topography of the mediastinum organs and accustoming to 
the particular view of the ultrasound anatomy is a prerequisite to reliable 
interpretation of the pictures. (19, 69) 
 
1.10 Cost-effectiveness:  
The sum of investment in any new machine is relatively large; the most important 
is cost of individual examination. Compensation for one EBUS examination is the 
sum total of: one conventional bronchoscopy, transbronchial flexible needle biopsy 
and ultrasound examination of one organ:  
 DM 100.- + 30.- + 20.- = DM 150.- (77 EUR)     
(Prices are based on the current fee schedules for medical services in Germany 
(GOÄ) (54).         
The assertion that EBUS is cost-effective (10), still remains to be validated by 
wider use in bronchial endoscopy. 
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1.11 Study hypothesis 
From the above discussion it is clear that most European studies on EBUS have 
been done in general anesthesia, using the rigid bronchoscope as a conduit for 
flexible scope to guide the ultrasonic probe to regions of interest. Since most 
routine diagnostic bronchoscopies are done in topical anesthesia, however, we 
studied the use of EBUS in topical anesthesia while aiming to validate the 
indications evolved using rigid procedures. Hence, this study aims to test two 
hypotheses: 
 1. EBUS provides valuable additional information for assessment of    
        lung cancer, compared to bronchoscopy and computer tomography,    
       and hence improves diagnostic rate. 
 2. The use of EBUS in bronchoscopy under topical anesthesia is practicable  
        despite some prolongation in the examination time. 
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2. Patients, Materials and Methods 
 
2.1 Recruitment of patients 
For this prospective study, we recruited 50 consecutive patients with suspected 
lung cancer undergoing diagnostic and/or staging FFB from October 2000 till 
October 2001.  
 
2.2 Inclusion criteria 
Patients should be able to give informed consent and have no contraindication for 
conventional fiberoptic bronchoscopy. 
Suspected lung cancer patients should have suspicious shadow(s) and/or 
mediastinal adenopathy in computed chest tomography  ± chest x-ray. 
     
2.3 Investigations 
The following investigations were performed routinely: 
full history and clinical examination, coagulation and routine blood studies, 
chest x-rays and computed chest tomography with contrast medium is done and 
evaluated prior to the endoscopic examination by the referring radiologist and 
bronchoscopist separately,  
fiberoptic bronchoscopic examination using 2.8-channel bronchofiberscope 
(Olympus 1T 40), 
endobronchial ultrasonographic examination under topical anesthesia during 
bronchoscopy to the areas of interest (details below). 
Samples taken for cyto-/histological examination were  documented in an 
accompanying examination protocol. 
 
2.4 Materials   
 
2.4.1 Specifications of the fiber bronchoscope (OES-BF 1T40, Olympus Optical 
Co. Ltd, Germany) are detailed below.  
                  Table 2: Specifications of the fiber bronchoscope  
Field of view 120° Optical system 
Depth of view 3~50mm 
Insertion tube Outer diameter Ø 6.0mm 
Distal end Outer diameter Ø5.9mm 
Working length                                            550mm 
Instrument channel Inner diameter Ø 2.8mm      
Bending section Range of the tip bending UP180°, Down 130° 
Total length                                             840mm 
High frequency compatibility                                             Yes  
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Main technical features of the EBUS system are as follows. 
 
Figure 4: System used for EBUS application (7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.2 Ultrasonic probe (UM-BS 20-26R, Olympus Optical Co. Ltd, Germany.) 
 
    Table 3: Functions, size and compatible endoscopes for ultrasonic probe 
Ultrasonic Functions 
Display mode  B-mode 
Scanning method Mechanical, radial scanning 
Scanning direction Perpendicular, to the direction of axis 360 degrees 
Frequency 20 MHz 
Contact method  
for site in question 
Balloon method 
Probe driving unit  
(MH-240)  
To drive ultrasonic probe in connection with the EU- M30   
                                                          
Size 
Working length (mm) 2050 
Total Length (mm) 2140 
Balloon Sheath outer diameter (mm) Ø 2.5 
Insertion tube diameter 
(including MAJ-643R balloon sheath) 
Ø2.6 
Compatible Endoscopes 
Scopes Channel inner diameter  
Flexible  Ø 2.8 (mm) or over 
Rigid Minimum capacity 9 Fr 
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2.4.3 Incorporated balloon sheath (MAJ-643R Olympus) 
 
         Table 4: Features of balloon sheath 
Balloon inflation with Distilled water 
Precautions No air bubbles inside 
Maximum inflation diameter Approximately 20 mm 
Distal end security  O-ring mechanism 
 
?Balloon preparation before use: The aim of the preparation is to test the balloon    
   inflation with distilled water, making sure that it contains no air bubbles.    
?Distal security mechanism of the balloon end: as soon as the amount of the 
   injected distilled water exceeds the inflation limit of the balloon, the O-ring at the 
   distal end is released and the distilled water is discharged from the distal end 
   deflating the balloon. The probe needs to be removed and set up again. 
   This mechanism prevents the balloon from bursting and dispersing loose pieces     
   inside the bronchus. 
 
Figure 5: Distal end of fiber bronchoscope with protruding ultrasonic 
probe with inflated balloon (7) 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.4 Endoscopic ultrasound center (EU-M30 Olympus) 
The endoscopic ultrasound center (EU-M30) controls the endoscopic ultrasonic 
probe inserted into the bronchi. The EU-M30 is able to receive, temporarily store 
and convert reflected echoes from the tissue into digital signals. The converted 
digital signals are displayed on the monitor. 
The EU-M30 probe is compatible with the video-endoscope (Olympus EVIS-BF) 
system and ordinary (OES BF) bronchofiberoscope system, enabling full operation 
of both systems. Although simultaneous observation of the endoscopic and 
ultrasonic images on one monitor is possible, it is preferable to have two monitors – 
one for endoscopic image, and one for ultrasound signals. 
 
                                   
                                                                                                                                                                    
                                                                                                                     20 
 
2.4.5 Aspiration needle 21 G (NA-2C, Olympus) 
This is a size 21 G fenestrated needle with a length of 13 mm, which is contained in 
a flexible catheter with a hand-operated, integrated proximal suction mechanism. 
 
2.5 Methods 
 
2.5.1 Patients preparation 
 1-An Intravenous line is introduced. 
 2-Premedication: 
    a) Atropine sulphate 0.5 mg is given intramuscularly 30 minutes before     
        bronchoscopy as well as  
    b) Pethidine 50 mg intramuscularly 30 minutes before bronchoscopy.  
    c) 100 mg prednisolone is given intravenously 90 minutes before      
        bronchoscopy in COPD patients to reduce the bronchial hyperreactivity (e.g.    
        cough and bronchospam). Additional dose of prednisolone is given the     
        night before bronchoscopy in patients with history of bronchial   
        hyperreactivity.    
3-Topical anesthesia: 
Inhalation of 5ml Lidocaine 4% solution with 2.5 mg Salbutamoul solution + 0.25 
mg Ipratropium bromide for 15 minutes is delivered before the procedure through 
an ultrasonic nebulizer.   
For further topical anesthesia during bronchoscopy, 2 ml aliquots of lidocaine 2%      
solution are instilled via the aspirating channel of the bronchoscope, up to a total    
maximum of 14 ml. 
4-Sedation: 
Titrated intravenous midazolam sedation is performed with all patients. 
Initially 3 mg are given, further increase are individually adjusted 
until speech becomes slurred or the patient sleeps. 
A benzodiazepine antagonist (flumazenil) is available for use to reverse occasional 
excessive sedative effects of midazolam. 
5-Oxygen supplement and patient monitoring:  
Administration of low flow (1 – 3 L/min) humidified oxygen transnasally, with  
pulse oxymetric monitoring is administered to all patients. 
The arterial oxygen saturation is continuously monitored during and   
immediately following the bronchoscopy and EBUS examination. 
 
2.5.2 Bronchoscopic – EBUS procedure  
With the patient in a recumbent position, the Olympus BF 1T 40 is introduced 
transnasally when possible, otherwise transorally. The bronchoscopic examination 
starts with careful inspection of the airways.  
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Then EBUS examination is performed as follows: 
A 20 MHz radial mechanical type ultrasound probe combined with a balloon (UM-
BS 20-26R) connected to an ultrasound unit (Driving unit MH-240 and Processor 
EU-M30, Olympus) is inserted through the working channel of fiberoptic 
bronchoscope, just beyond the tip of the FFB to the areas of interest under direct 
vision. The balloon is inflated with distilled water until the bronchial lumen is fully 
occluded, thus ensuring a complete coupling between transducer and the bronchial 
wall. A motor in the ultrasound unit rotates the transducer within the catheter, 
producing a cross-sectional 360° ultrasound image, which is oriented at a right 
angle to the axis of the catheter. The endoscopic and ultrasonic images are 
immediately available for viewing on the monitor (real time). Individual freeze-
frame images are printed out. All examinations are recorded by videotape for later 
analysis and storage.   
? Scanning of the trachea: In the trachea partial inflation of the balloon up to 60 
seconds is performed, while pushing the probe towards the suspected site of   
tracheal wall, during which anatomical and pathological structures are quickly 
visualized. Then a freeze frame image is taken and analyzed more closely after 
balloon deflation.       
? Scanning of the central bronchi: During EBUS scanning of the central bronchi, 
the bronchial lumen is obstructed between 30 to 120 seconds with the inflated 
balloon, during which anatomical and pathological structures are visualized. Then a 
freeze frame image is taken and meticulously studied after balloon deflation.       
? Scanning of peripheral bronchi: In the peripheral bronchi, the lumen can be 
occluded for longer durations than central bronchi. In more peripheral smaller 
caliber bronchi, a 360° coupling without air interposition can be achieved some 
times without balloon inflation. 
? Localization of a lesion in relation to the bronchial lumen: 
After deflation of the balloon, the level of the ultrasonic transducer probe (black in 
color) is recorded in relation to the adjacent anatomical landmarks (e.g. cartilages, 
bronchial branches). The anatomical position of the suspected lesion is described as 
its clock position on the ultrasonic image. (i.e. for location of the suspected lesion 
in relation to the tracheobronchial tree is best visualized by imaging the interior of 
the airways as a clock face.)  
 
2.5.3 Transbronchial needle aspiration 
Transbronchial needle aspiration from the suspected lesions using a 21 G aspiration 
needle is sequentially done after prior EBUS localization. Other bronchoscopic 
samples (bronchial biopsy, transbronchial lung biopsy, bronchial brushing and 
bronchial wash) are taken whenever needed. 
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T.B.N.A Technique: 
The “jabbing method” is used to insert the needle through the airway wall as 
described by Wang (89). With the tip of the scope straight and at midtrachea, the 
needle is inserted through the scope while its tip is inside the metal hub. When the 
metal hub is visualized, the needle is advanced and locked into place. The whole 
catheter, with the locked needle, is withdrawn to a point where only the very distal 
tip of the needle is visible through the bronchoscope. Then the bronchoscope is 
advanced to the target area. When the puncture site is identified and reached, the tip 
of the scope is bent maximally toward the puncture site. While the assistant fixes 
the scope at the nose or mouth, the operator grasps the proximal portion of the 
catheter and then the needle is thrust through the intercartilaginous space with a 
quick firm jab to the catheter.  
 
2.6 Complications 
A-Complications related to the EBUS procedure: 
Complications of the procedure were recorded and graded as mild, moderate or 
forcing to abandon the procedure: 
1-Cough: [Mild (less than 3 episodes), moderate cough or cough terminating the  
                 examination]. 
2- Desaturation:  
    ?Mild (oxygen saturation 90 -95%)® No effect on examination.  
    ?Moderate (oxygen saturation 85 - 89%)® Affected examination  
     (prolongation of duration -other effects.)        
    ?Aborted examination. (oxygen saturation  <85%) 
The patient tolerance score is plotted based on complications encountered:     
1- Complete tolerance (no complications).  
2- Partial tolerance (mild to moderate complications).  
3-No tolerance (procedure aborted). 
B-Complications related to TBNA is recorded if occurred.  
   
2.7 Instrument handling difficulties  
Instrumental handling difficulties as difficulties in the balloon sheath preparation 
before and during use, imaging artifacts, image adjustment difficulties and 
orientation difficulties related to the instrument or any other encountered during 
study would be registered.   
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2.8 Statistical analysis 
The data collected are tabulated and analyzed statistically; the following methods 
are used to express the results obtained:       
?The diagnostic ability of EBUS to detect central, peripheral and combined 
lesions: In the context of testing the diagnostic ability of EBUS to detect central, 
peripheral and combined lesions, combined FFB (with histology and/or cytology) 
and CT findings were considered as gold standard. 
EBUS detection rate (DR) of central tumors = truly positively detected central 
lesions / truly positively + falsely negative detected central lesions. 
EBUS DR of peripheral tumors = truly positively detected peripheral lesions / truly 
positively + falsely negative detected peripheral lesions. 
The previous method is used to calculate EBUS DR of combined central and 
peripheral tumors. 
To test the significant difference in the detecting capability of EBUS between 
central and peripheral tumors, the chi-squared (X2) significance test was used; a P-
value is produced and gives the probability of the observed results under the null 
hypothesis.     
?Testing the additional information provided by EBUS versus FFB & CT:  
In the perspective of testing the additional information provided by EBUS the 
interest was on the additional data EBUS could provide and not suspected 
radiologically or endoscopically, in the form of further lymph nodes, bronchial wall 
invasion and its depth and blood vessel impression or infiltration. 
Additional information provided by EBUS = number of patients in whom an 
additive information was detected by EBUS (e.g. LNs & /or bronchial wall 
invasion and its depth & /or blood vessel impression or infiltration) and not 
suspected by FFB & CT  / number of all patients in whom additive information was 
examined  
Additional information provided by FFB & CT = number of patients in whom an 
additive information was detected by FFB & CT by failed to be detected by EBUS  
/ number of all patients in whom additive information was examined. 
To test the significant difference in the additional information provided by EBUS 
versus FFB & CT, the chi-squared (X2) significance test was used; a P-value is 
produced and gives the probability of the observed results under the null 
hypothesis.     
The additional information was evaluated on a per-patient basis, not per single 
additive information, as the former is more indicative of consequences following 
this additive information in each case. 
? Testing LNs DR:  
EBUS & CT LNs DR = number of LNs detected by both EBUS & CT / total 
number of LNs examined.  
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EBUS LNs DR = number of LNs detected by EBUS only / total number of LNs 
examined.  
CT LNs DR = number of LNs detected by CT only / total number of LNs 
examined.  
Total EBUS LNs DR = number of LNs detected by EBUS & CT + EBUS only / 
total number of LNs examined.  
Total CT LNs DR = number of LNs detected by EBUS & CT + CT only / total 
number of LNs examined.  
To test the significant difference in detection of LNs between EBUS and CT, the 
chi-squared (X2) significance test was used; a P-value is produced and gives the 
probability of the observed results under the null hypothesis.     
?Diagnostic yield of EBUS-assisted TBNA of EBL and LNs: 
Diagnostic yield of EBUS-assisted TBNA of EBL = number of detected and 
diagnosed EBL by EBUS-assisted TBNA / total number of EBL examined by 
EBUS-assisted TBNA. 
Diagnostic yield of EBUS-assisted TBNA of LNs = number of detected and 
diagnosed LNs by EBUS-assisted TBNA / total number of LNs examined by 
EBUS-assisted TBNA. 
 
The 95% confidence interval (95% CI) is calculated to assess the clinical 
significance of the estimated range of the result.   
?Patient tolerance score: is plotted on the basis of complications encountered.  
Complete tolerance = Number of patients examined by EBUS without 
complications / total number of patients examined by EBUS 
Partial tolerance = Number of patients examined by EBUS with presence of mild to 
moderate complications / total number of patients examined by EBUS. 
No tolerance = Number of patients in which EBUS examination was aborted / total 
number of patient examined by EBUS. 
? Calculating the proportion of the EBUS examination from the total time of 
bronchoscopy = Duration of EBUS examination / total examination time x 100 
In the current study, for statistical calculations the following program was used:  
EpiCalc2000 Statistical Program, version 1.02, Joe Gilman and Mark Myatt, 1998. 
Brixton Books. 
Different detection rates (DR) presented in this study were compared using  
the uncorrected chi-square and p-value for a series of proportions (expressed as 
percentages) and sample sizes. 
 
The method used to calculate the chi-square statistic is described in: 
Kirkwood BR, Essentials of Medical Statistics, Blackwell Scientific Publications, 
1988, ISBN 0-632-01052-5, pp. 91-92 
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The method used to calculate the p-value for the chi-square statistic uses the 
method described by Lau (Lau CL, Algorithm AS 147. A Simple Series for the 
Incomplete Gamma Integral, Applied Statistics, 29,113 - 114, 1980) and is adapted 
from an algorithm presented in: 
Cooke D, Craven AH, Clarke GM, Basic Statistical Computing (Second Edition), 
Edward Arnold, 1990, ISBN 0-340-53919-4, pp. 84-94 
The 95% confidence interval (95% CI), was calculated with the help of: 
Ciba Geigy Scientific Tables, 1980, 2nd edition, Basle, Switzerland.  
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3. Results 
 
3.1 Overview on results of all cases studied  
 
3.1.1 Patients characteristics and lesions location, biopsy technique and final  
         pathology  
Out of 50 patients with suspected lung cancer in this study, 36 were male and 14 
were female. Their ages ranged between 36-89 years, with a mean age of 62.4 ± 
12.3 years (Table 5).  
 
Table 5: Patients characteristics and lesions location, biopsy technique and final                 
               pathology 
Case Age 
(Y) 
Sex Location Biopsy /Lesion Final Pathology 
1 74 M C TBNA /LN Inflammatory 
2 54 F C TBNA /PBL Adenocarcinoma 
3 41 F C TBNA /PBL Adenocarcinoma 
4 63 M C TBNA /PBL SCLC 
5 73 M C TBNA /LN Adenocarcinoma 
6 61 M P TBLB & BW/ PL Squamous cell CA 
7 70 F C TBNA /PBL & LN Squamous cell CA 
8 75 M C TBNA /PBL Mixed cell carcinoma 
9 43 F C TBNA /PBL & LN Adenocarcinoma 
10 70 M C TBNA /PBL Mixed cell carcinoma 
11 64 M C BB / BL Mixed cell carcinoma 
12 45 M C TBNA /LN Inflammatory 
13 49 M C TBNA /LN SCLC 
14 63 M C TBNA /PBL NAD 
15 45 M C TBNA /BL SCLC 
16 70 M P TBNA /PBL Squamous cell CA 
17 76 M C TBNA /PBL Severe Dysplasia 
18 40 F C TBNA &BAL /LN Sarcoidosis 
19 58 F P TBNA /PBL Inflammatory 
20 45 F P TBLB /PL Adenocarcinoma 
21 62 M C TBNA /PBL NAD 
22 64 M P TBNA&TBLB /LN & PL Adenocarinoma 
23 45 M P TBNA& TBLB /2 LN &PL SCLC 
24 89 F C BB / BL Large cell carcinoma 
25 63 M P TBLB / PL SCLC 
26 64 M C TBNA /PBL SCLC 
27 76 M P TBNA /PBL Squamous cell CA 
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Case Age 
(Y) 
Sex Location Biopsy /Lesion Final Pathology 
28 71 M C TBNA /PBL Adenocarcinoma. 
29 73 M C TBNA /PBL Squamous cell CA 
30 63 M C BB / BL SCLC 
31 64 M C&P TBNA/LN Inflammatory (TB) 
32 74 M C&P TBNA /PBL & PL Squamous cell CA 
33 54 F C TBNA /LN Adenocarcinoma 
34 75 M C TBNA /LN NRS 
35 57 F P BAL &TBNA / PL &LN PL=NAD & LN=NRS  
36 52 M C --------- ** 
37 69 F P TBLB  / PL Adenocarcinoma 
38 59 F C TBNA /LN Inflammatory 
39 70 M C TBNA /LN Inflammatory 
40 36 M C TBNA /BL & PBL Squamous cell CA 
41 47 F P TBLB / PL Adenocarcinoma 
42 69 M C TBNA&BB / LN & BL Squamous cell CA 
43 64 M C TBNA / LN& PBL Adenocarcinoma 
44 59 M C TBNA / LN Squamous cell CA 
45 81 M C BB / BL SCLC 
46 82 M P Brush / PL Adenocarcinoma 
47 56 F P TBLB &TBNA / PL & LN Adenocarcinoma 
48 78 M P TBLB / PL Squamous cell CA 
49 58 M C TBNA / LN Inflammatory 
50 67 M C TBNA / LN Adenocarcinoma 
 
M = male, F = female, C = central lesion, P = peripheral,  LN = lymph node, PBL = Peribronchial lesion, 
BL= bronchial lesion, PL = peripheral lesion, TBNA = Transbronchial needle aspiration,  
TBLB = Transbronchial lung biopsy, BB = Bronchial biopsy, BW = Bronchial wash, BAL = Bronchoalveolar 
lavage, Brush = protected catheter brush, SCLC = Small cell lung cancer, NAD = no abnormality detected, 
NRS= Non-representative sample, TB= Tuberculosis, CA = carcinoma, ** = no tumor infiltration to the 
trachea, in a case of cancer esophagus, confirmed surgically. 
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3.1.2 Results of additive information provided by FFB & CT / EBUS 
and EBUS explanation of FFB findings (Table 6) 
 
     Table 6: Results of additive information provided by FFB & CT / EBUS                        
                    and EBUS explanation of FFB findings  
EBUS provided additional information Case 
 
FFB  and CT 
provided more 
data 
than EBUS 
EBUS 
explanation 
of the FFB 
findings 
 
Lymph 
nodes 
Bronchial wall 
invasion 
Blood vessel 
infiltration 
or 
impression 
1 1 LN - ve 2 - - 
2 1 LN + ve 3 - Impression 
3 - + ve 1 Invasion from 
outside the 
bronchial wall 
- 
4 - + ve - Invasion of 
cartilage 
- 
5 1 LN - ve - - - 
6 1 PL + ve 1 - - 
7 - + ve - Beyond adventitia - 
8 - + ve 1  Invasion from 
outside the 
bronchial wall 
- 
9 1 LN - ve 1 - - 
10 - + ve - Beyond adventitia - 
11 - - ve - Beyond adventitia - 
12 - - ve - - - 
13 - + ve - Beyond adventitia Impression 
14 - + ve - Beyond adventitia - 
15 - + ve 1 Beyond adventitia - 
16 - + ve 1 Invasion from 
outside the 
bronchial wall 
- 
17 - + ve 1 Beyond adventitia - 
18 - - ve 1 - - 
19 - - ve - - - 
20 - - ve 1 - - 
21 - - ve - Beyond adventitia - 
22 1 LN + ve - Beyond adventitia - 
23 - - ve 3 Invasion from 
outside the 
bronchial wall 
- 
24 2 LN - ve - - - 
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EBUS provided additional information Case 
 
FFB  and CT 
provided more 
data 
than EBUS 
EBUS 
explanation 
of the FFB 
findings 
 
Lymph 
nodes 
Bronhial wall 
Invasion 
Blood vessels 
infiltration 
or 
impression 
25 - + ve 1 - - 
26 - + ve 2 Invasion of adventitia 
& LN invading 
bronchial wall  
- 
27 - - ve - - - 
28 - - ve - - - 
29 - + ve - - - 
30 - - ve - - - 
31 - + ve 3 - - 
32 - - ve - - - 
33 - - ve - - - 
34 - - ve - - - 
35 1 PL - ve 1 - - 
36 1 LN - ve 1 - - 
37 - + ve - Invasion of cartilage - 
38 - - ve 1 - - 
39 - - ve 2 - - 
40 - + ve - Beyond adventitia - 
41 - - ve - - - 
42 - + ve - - - 
43 - + ve 1 Beyond adventitia - 
44 - - ve 1 - - 
45 - + ve - Invasion of cartilage - 
46 - - ve - Beyond adventitia  
47 1 LN - ve 1 Beyond adventitia - 
48 - - ve - - - 
49 - - ve - - - 
50 - - ve 1 - - 
 
LN = lymph node, PL = peripheral lesion, FFB = Flexible fiberoptic bronchoscopy, CT = computerized 
tomography, + ve = positive findings, EBUS helped in explanation of bronchoscopic findings and – ve = 
negative bronchoscopic findings. 
 
3.2 Pathological results of all studied cases  
Pathological verifications were as follows (Table 7): 36 patients had lung cancer, 7 
patients had inflammatory lesions (5 were lymphocytic hyperplasia of enlarged LN, 
one case of tuberculous lymphadenitis and another case with a non-specific 
inflammatory lesion), a case of sarcoidosis, and one patient had severe dysplasia 
suspicious of malignancy. In three cases, pathological results showed no 
abnormality. A non-representative sample had been obtained in one case.  
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In the case of cancer of the esophagus, no tumor infiltration to the trachea wall had 
been detected with EBUS and this was confirmed later surgically.  
 
       Table 7: Pathological results of all studied cases.  
Pathological results N Total 
Malignant: 
Adenocarcinoma  
Squamous cell carcinoma 
Small cell lung cancer 
Large cell lung cancer 
Mixed cell type 
 
14 
10 
8 
1 
3 
36 
Inflammatory: 
Lymphocytic hyperplasia of lymph nodes 
Tuberculous lymphadenitis 
Non–specific inflammatory lesion 
 
5 
1 
1 
7 
Others: 
Sarcoidosis 
No abnormality detected 
Severe dysplasia suspicious of malignancy 
Non-representative sample 
* Cancer esophagus 
 
1 
3 
1 
1 
1 
7 
  
*A case of esophageal cancer (number 36): No tumor infiltration of the central airways was 
postulated with EBUS and confirmed surgically. 
 
In follow up, all inflammatory lesions were free from malignancy. 
(2 out of 5 lymphocytic hyperplastic LN were confirmed by mediastinoscopy, the 
other 3 were followed up without evidence of malignancy for more than 6 months. 
A para-cardiac space occupying lesion with non-specific inflammatory results 
proved to be organized pneumonia with complete resolution and no further 
recurrence until 7 months later.)  
Follow up of NAD cases confirmed one case as free from malignancy (true 
negative; Lt upper lobe lung shadow and enlarged LNs, on thoracotomy were found 
to be chronic organized pneumonia, anthracosis and chronic lymphadenitis). 2 
further cases proved to be malignant (false negative).  
Malignancy was revealed on further diagnostic work up of the case with severe 
dysplasia (false negative).  
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Figure 6: Actual endoscopic view during EBUS application.  
 
 
 
 
 
 
 
 
 
 
 
 
US probe with inflated balloon at its distal end at the region of the proximal right main 
bronchus and main carina, notice the complete coupling between the inflated balloon 
and bronchial wall for achievement of good image quality.  
 
3.3 EBUS Applications sites 
 
Figure 7: Number of EBUS applications in each position in 50 patients. 
 
RMB(15) Tr(8)
BI(7)
RUL(10)
RB1(3)
RB2(1)
RB3(3)
RB4(2)
ML(3)
RB5(2)
RB6(2)
RB7(2)
RLL(4)
LMB
P(5)
M(11)
D(8)
LB1-2(4)
LUL(15)
Li(1)
LB6(3)
LLL(4)
 
 
The numbers of EBUS applications in different positions were 114 applications in 
50 patients (Figure 6, 7) (table 8). 
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         Table 8: Distribution of EBUS application sites 
                                                               Trachea (T) =N 8   
Application site N Application site N 
Lt. tracheobronchial tree: 
Lt. main bronchus (LMB) 
proximal(P) LMB 
middle(M) LMP 
distal(D) LMP 
Lt. upper lobe bronchus (LUL) 
Lt. apico-posterior (LB1&2) 
Lingula (Li) 
Lt. lower lobe bronchus (LLL) 
Lt. superior basal (LB6) 
Lt. anterior basal (LB8) 
52 
 
5 
11 
8 
15 
4  
1 
4 
3 
1 
Rt. tracheobronchial tree:  
Rt. main bronchus (RMB) 
Rt. upper lobe bronchus (RUL) 
Apical (RB1) 
Posterior (RB2)  
Anterior (RB3) 
Bronchus intermedius (B.I) 
Middle lobe bro nchus (ML)  
Medial (RB5) 
Lateral (RB4)  
Rt. lower lobe bronchus (RLL) 
Superior basal (RB6)          
Medial basal (RB7) 
54 
15 
10 
3  
1 
3 
7 
3 
2 
2 
4 
2 
2 
 
3.4 Structures identified by EBUS 
In all the 50 cases, satisfactory images could be obtained, recorded and studied.  
 
3.4.1 Blood vessels 
Blood vessels were recognized as echo-free or relatively hypoechoic structures 
with variable appearances. Arteries were identified by strong obvious pulsation. 
Veins had weaker pulsatile changes. Differentiation between arteries and veins was 
sometimes difficult, especially in the right and left lower lobes, because of the wide 
variation in the positions and the numerous small caliber branches of the 
pulmonary arteries and veins in these areas.  
Also some cardiac structures were identified as the left and right atrium. 
 
3.4.2 Esophagus 
The esophagus appeared as an oval, triangular or linear-shaped multi-layered 
structure, dorsal to the trachea and the left main bronchus. 
 
3.4.3 Lymph nodes 
Lymph nodes appeared as hypoechogenic structures with discrete borders in their 
usual anatomical position. They are ovoid, rounded, triangular or elliptical in shape. 
However, there are exceptions. A hyperechogenic center was recognized in one 
case representing the hilum of the node. In another, the nodes appeared as 
hypodense irregular structures without the characteristic lymph node configuration.  
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The outer border of pathologically enlarged lymph nodes were sometimes beyond 
the EBUS range, thus making it difficult to measure lymph node diameters in all 
cases, but when measured it ranged between 0.4 cm to 2.5 cm.  
 
3.4.4 Tumor 
The detected masses appeared as hypoechoic structures with different degrees of 
hypoechogenicity, having irregular margins and taking abnormal shapes with no 
respect to the surrounding anatomical structures.  
 
3.4.5 Normal lung parenchyma  
Appeared hyperechogenic.    
 
3.4.6 Laminar structure of the bronchial wall 
The multi-layers of the bronchial wall are not easily identifiable in many instances. 
The third marginal layer (inner-side border of the cartilage or cartilage-
endochondrium) and the fourth layer (bronchial cartilage) appear as 
hyperechogenic, hypoechogenic layers respectively, near the middle part of the 
bronchial wall. This was a helpful landmark for identifying the layers of bronchial 
wall. Bronchial wall layers lying towards its inner aspect (i.e. between it and the 
bronchial lumen), are the first and second layers mucosa and submucosa. The layer 
towards its outer aspect is the fifth layer (adventitia). Depth of tumor invasion was 
identified by its relation to the third and fourth layers.  
 
3.5 Locations of lesions (central, peripheral or combined) 
The lesions were classified into central, peripheral or combined lesions based on 
combined FFB and radiological (CT) findings. 
Central lesions are either visible endoscopic bronchial masses or radiologically 
apparent extraluminal masses up to the level of second–order bronchi. 
Peripheral lesions start at the third order or more distal bronchi.  
Combined lesions are cases where central and peripheral lesions detected (Table 9). 
 
Table 9: Location of   lesions in 50 patients based on combined FFB     
                and CT findings.   
Location  ?  Malignant  Inflammation Others 
Central 34 23 5 6 
Peripheral 14 12 1 1 
Central 
&Peripheral 
2 1 1 0 
Total 50 36 7 7 
? = sum  
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Out of 50 cases studied by FFB and CT (Table 10), EBUS detected all the 34 
central lesions (100%), out of 14 cases with peripheral lesions 12 were detected 
with EBUS (86 %), while 2 cases were not detected (14%). The 2 combined lesions  
were detected with EBUS (100%). 
 
       Table 10: EBUS detection of lesions in the 50 cases studied 
                EBUS Localization FFB & CT 
N DR (%) 95% CI 
Central 34 34 100 89.4-100 
Peripheral 14 12 86 57.2-98.2 
Combined 2 2 100 15.8-100 
N = number. DR = detection rate.   CI = confidence interval.  
 
In 36 cases pathologically verified lung cancer (Table 11), EBUS detected all 23 
cases with central lesions (100%) and 11 out of 12 peripheral lesions (92%) and 
failed in detecting one case (8%). A case with combined central and peripheral 
lesions was detected (100%).  Thus EBUS detected 35 out of 36 pathologically 
verified lung cancer (97%) and failed in detecting one peripheral lesion (3%). 
EBUS has equal detecting capability for central and peripheral lesions (Table 12). 
 
Table 11: EBUS detection of central and peripheral lesions in 36 cases   
                  pathologically verified lung cancer 
Detected Non-detected  
 
Localization 
 
 
N 
 
N 
 
DR 
(%) 
 
 
95% CI 
 
N 
 
DR (%) 
Central 
tumors 
23 23 100 85.2-100   
Peripheral 
tumors 
 
12 11 92 61.5-99.8 1 8 
Combined 
C& P      
tumors 
 
1 
 
1 
 
100 
 
 
  
Total 36 35 97 85.4-99.9 1 3 
C = Central P = Peripheral N = number DR = detection rate   CI = confidence interval 
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Table 12: Comparison of EBUS capability to identify central and peripheral   
            lesions in 36 cases pathologically verified lung cancer 
Central tumors Peripheral tumors  
 
Detected   
lesions 
 
DR (%) 
 
 
95% CI 
 
Detected   
lesions 
 
DR 
(%) 
 
95% CI 
 
P-value 
23/23 100 85.2-100 11/12 92 61.5-99.8 P > 0.05 
There were non-significant difference (P > 0.05) in EBUS detection rate between central 
and peripheral tumors, thus EBUS has equal detecting capability in detecting central and 
peripheral tumors. 
 
*Clarification and specification of 4 central lesions: 
In four cases with central lesions, EBUS was more precise than CT in detecting and 
clarifying these lesions. In 3 of these cases, CT detected the lesion as central mass 
lesion without further details. By EBUS, these lesions were more precisely 
identified as enlarged lymph nodes with specification of their number, size, 
location and surroundings structures. 
In the fourth case, CT identified the lesion as a subcarinal soft tissue mass 
suspicious of mediastinal lymphadenopathy. By EBUS, this lesion was more 
precisely identified and assessed to be a central right upper lobe bronchus tumor 
with Rt. and Lt. subcarinal lymphadenopathy. 
 
Characterizing a lesion as a lymph node takes into account similar sonographic 
patterns of lymph nodes in other areas of the body and appearance of cytologically 
verified nodes from previous EBUS experience. Similarly, tumor identification was 
based on characteristic sonographic patterns of histologically proven tumors. 
 
3.6 Additional information provided by EBUS  
In all areas examined by EBUS and other conventional methods (CT and FFB), 
agreement about the main features of disease process was reached, but the main 
interest was on the additional data EBUS provided compared to other methods. 
In 35 out of 50 cases (70%) EBUS provided additional data more than FFB and 
CT. On the other hand, FFB and CT provided additional data more than EBUS in 
10 out of 50 cases (20%) (Table 13). 
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     Table 13: Additional data provided by EBUS /FFB &CT in 50 patients 
Cases EBUS provided 
additional  data more  than 
FFB & CT 
FFB & CT provided 
additional data more 
than EBUS 
 
 
 
N N R (%) 95% CI N R (%) 95% CI P-value 
50 35 70 55.4-82.1 10 20 10.2-33.7 P<0.005 
N = number. R = rate.   CI = confidence interval. 
Statistically the additional data provided by EBUS were highly significant as compared to 
the additional data provided by FFB and CT (P < 0.005) (Table 13).  
 
In pathologically verified lung cancer, EBUS provided additional data more than 
FFB and CT in 25 out of 36 cases (69%). On the other hand, FFB and CT provided 
additional data more than EBUS in 7 out of 36 cases (19%)(Table 14). 
 
Table 14: Additional data provided by EBUS versus FFB & CT in 36 cases of 
pathologically verified lung cancer 
 
Cases 
EBUS provided data 
in addition to FFB & CT 
FFB & CT provided data 
in addition to EBUS 
 
 
N N R (%) 95% CI N R (%) 95% CI P-value 
36 25 69 51.9-83.7 7 19 8.19-36 P < 0.005 
N = number. R = rate.   CI = confidence interval. 
Statistically the additional data provided by EBUS were highly significant as compared to 
the additional data provided by FFB and CT (P < 0.005) (Table 14).  
 
The additional data provided by EBUS as opposed to other conventional methods 
(FFB and CT) were in position and number of lymph nodes, bronchial wall 
invasion and the differentiation between compression or infiltration of blood 
vessels.   
 
3.6.1 Lymph nodes 
The lymph nodes studied were classified into three groups according to the method 
of detection: LNs detected by CT and EBUS, by EBUS only, or by CT only.  
 
Criteria for LNs detected by EBUS and CT: Characterizing a lesion identified 
by EBUS as a lymph node takes into account that it takes a typical similar 
sonographic pattern of lymph nodes in other areas of the body and in previous 
EBUS experience and taking usual site of lymph node station. The same LNs were 
also detected by CT and cytological confirmation was obtained in a group of them.   
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Criteria for additional LNs provided by EBUS only: Characterizing an additive 
LN identified by EBUS only as a typical similar sonographic pattern of lymph 
nodes in other areas of the body and in previous EBUS experience. It presents at a 
usual lymph node station with cytological verification obtained in a group of them.  
In addition, confirmation was achieved by mediastinoscopy in two of them.   
Criteria for LNs detected by CT only: LN detected by CT and failed to be 
identified by EBUS (No suggestive sonographic pattern of LN). 
 
Totally 86 lymph nodes were detected, 45 lymph nodes (52%) were detected by CT 
and EBUS, 32 lymph node (37%) by EBUS only and 9 lymph node (11%) by CT 
only (Table 15). 
 
          Table 15: Lymph nodes detected by EBUS/CT in 50 patients 
 
LN 
Detected by 
EBUS and CT 
 
Detected by 
EBUS only 
 
Detected by 
CT only 
N N DR (%) 95% CI N DR 
(%) 
95% CI N DR (%) 95% CI 
86 45 52 41.3-63.2 32 37 27-48.3 9 11 4.9-18.4 
N = number. DR = detection rate.   CI = confidence interval. 
 
In all studied cases, the total number of LN detected by EBUS was 77 out of 86 
(90%) LN studied, while the total number of LN detected by CT was 54 out of 86 
(63%) (Table 16).  
 
  Table 16: Comparison between total number of LN detected by EBUS      
                    to CT in 50 patients 
 
LN 
Total number of LN 
detected by EBUS 
Total number of LN 
detected by CT 
 
N N DR 
(%) 
95% CI N DR 
(%) 
95% CI P-value 
86 77 90 81.1-95.1 54 63 51.7-72.9 P <0.005 
N = number. DR = detection rate.   CI = confidence interval. 
In all studied cases, the total number of LNs detected by EBUS when compared with 
those detected by CT showed a highly significant difference (P < 0.005) (Table 16).  
 
The LNs detected by EBUS only were 32 LNs, while the LNs detected by CT only 
were 9 LNs in all studied cases (Table 17). [LNs numbering is after reference (51).] 
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Table 17: Localization of lymph nodes detected by EBUS only or by CT only in all  
                 studied cases 
LN localization By EBUS only (32 LNs) By CT only (9 LNs) 
Rt lower paratracheal LN (4R) - 5 
Lt subaortic (Aorto-Pulmonary) LN (5L) 7 - 
Lt para-aortic LN (6L) - 2 
Rt subcarinal LN (7R) 1 1 
Paraoesophageal LN (8) 1 - 
Rt hilar LN (10R) 6 1 
Lt hilar LN (10R) 1 - 
Rt interlobar LN (11R) 2 - 
Lt interlobar LN (11L) 5 - 
Rt lobar LN (12R) 4 - 
Rt segmental LN (13R) 2 - 
Lt segmental LN (13L) 3 - 
 
In 36 cases pathologically verified lung cancer, 55 lymph node were detected, 28 
lymph nodes (51%) were detected by CT and EBUS, 20 lymph nodes (36%) by 
EBUS only and 7 lymph nodes (13%) by CT only (Table 18). 
 
          Table 18: Lymph nodes detected by EBUS/CT in 36 cases  
                            pathologically verified lung cancer 
 
LN 
Detected by 
EBUS & CT 
 
Detected by 
EBUS only 
 
Detected by 
CT only 
N N DR 
(%) 
95% CI N DR 
(%) 
95% CI N DR 
(%) 
95% CI 
55 28 51 37.1-64.7 20 36 23.8-50.4 7 13 5.3-24.5 
N = number. DR = detection rate.   CI = confidence interval. 
 
 
 
 
 
 
 
 
 
                                   
                                                                                                                                                                    
                                                                                                                     39 
 
Figure 8:  An example of an additive LN provided by EBUS only 
     a)              b)  
 
a) CT scan cut shows pulmonary artery (PA) and an enlarged Rt hilar LN surrounding    
     bronchus intermedius.  
b) EBUS in bronchus intermedius (BI), showing Rt hilar LN medially, pulmonary artery    
    (PA) and an additive enlarged Rt interlobar LN (#11R) postero-lateral not seen in CT.  
 
In 36 cases of pathologically verified lung cancer, the total number of LNs detected 
by EBUS was 48 out of 55 (87%) LN studied, while the total number of LNs 
detected by CT was 35 out of 55 (64%) (Table 19).  
 
  Table 19: Comparison between total number of LN detected by EBUS     
                    to CT in 36 cases with pathologically verified lung cancer. 
 
LN 
Total number of LN 
detected by EBUS 
Total number of LN 
detected by CT 
 
N N DR (%) 95% CI N DR (%) 95% CI P-value 
55 48 87 75.5-94.7 35 64 49.6-76.2 P < 0.005 
N = number. DR = detection rate.   CI = confidence interval. 
In 36 cases pathologically verified lung cancer, the total number of LNs detected by 
EBUS when compared with those detected by CT showed a highly significant difference 
(P < 0.005) (Table 19).  
 
 
 
 
LN 
PA 
 
LN 
PA 
 
LN 
PA 
BI 
LN 11 R 
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Figure 9: An example of EBUS application in the trachea.  
   a)      b) 
 
a) CT scan cut showing an enlarged big Rt lower paratracheal LN (#4 R) lying anterior to   
    the trachea and a smaller node (#4R) posteriorly. 
b) EBUS in the trachea showing more detailed nodal distribution with 2 enlarged Rt   
    lower paratracheal LN (#4 R) lying anterior to trachea in addition to a posterior node. 
    (AO= Aortic arch, AZ= Azygos vein and TR = Trachea)    
 
The LNs detected by EBUS only, in 36 pathologically verified lung cancer cases 
were 20 LNs, while 7 LNs were detected by CT only (Table 20).  
 
 Table 20: Localization of lymph nodes detected by EBUS only or by CT only   
                  in pathologically verified lung cancer  
LN localization  By EBUS only (20LNs) By CT only (7LNs) 
Rt lower paratracheal LN (4R) - 4 
Lt subaortic (Aorto-Pulmonary) LN (5L) 6 - 
Lt para-aortic LN (6L) - - 
Rt subcarinal LN (7R) 1 1 
Rt hilar LN (10R) 1 1 
Lt hilar LN (10R) 1 - 
Rt interlobar LN (11R) 1 - 
Lt interlobar LN (11L) 4 - 
Rt lobar LN (12R) 3 - 
Lt segmental LN (13L) 3 - 
 
3.6.2 Bronchial wall invasion 
Criteria of identification of bronchial wall invasion by EBUS additionally:  
Characterizing tumor invasion of a bronchial wall as additional information 
provided by EBUS takes in account the characteristic sonographic patterns and 
alterations of tumor in bronchial wall observed by EBUS and not by CT and its 
histological verification to be malignant through bronchoscopic biopsy. However, 
biopsy could not confirm the exact depth of invasion, which was ascertained by 
LN 
LN 
AO 
AZ 
TR 
LN 
LN 
LN 
AO 
AZ 
TR 
LN 
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EBUS images only. 
In pathologically verified lung cancer patients (36), tumor invasion of the bronchial 
wall was identified in 21 cases.  
The distribution of extent was as follows: 
- Invasion beyond the adventitia: 13 cases.  
Tumor invading all bronchial wall layers and extending beyond the adventitia. 
- Invasion of the adventitia and lymph node invading the bronchial wall: 1 
Tumor invading up to adventitia associated with lymph node invading from outside 
the bronchial wall layers up to the submucosa, but with intact mucosa (case 26).  
- Invasion of cartilage: 3 cases. 
Tumor invading up to the cartilage. The tumor has a special appearance, it invades 
submucosa and cartilage, lying between the intact mucosa and adventitia. (in cases 
4, 37 and 45). 
- Tumor invading from outside the bronchial wall: 4 cases.  
Tumor invading from outside the bronchial wall up to the cartilage (all cartilage 
layers are invaded) with intact mucosa and submucosa (cases 3,16 and 23). 
In case number 8, tumor invades from the outside of the bronchial wall up to 
bronchial cartilage (fourth layer) with intact marginal echo at inner-side border of 
cartilage (third layer), mucosa and submucosa. 
 
Figure 10: An example of bronchial wall invasion and depth diagnosis.  
 
EBUS in Lt lower lobe: Localised area of hypoechogenic tumor mass invading from 
outside the bronchial wall up to bronchial cartilage (fourth layer) with intact marginal 
echo at inner-side border of cartilage (arrow) (third layer), mucosa and submucosa. The 
pulmonary artery (PA) and vein (PV) of the Lt lower lobe appear as an echo free area 
easy to differentiate during motion.   
 
PV 
PA 
LLLB 
PV 
TU 
PA 
C 
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3.6.3 Infiltration or Impression of blood vessels  
In 2 cases impression of pulmonary arteries (Lt upper lobe pulmonary artery and Lt 
lower lobe pulmonary artery) by enlarged lymph nodes were identified and was 
based on the sonographic pattern of the impression of vessels observed in other 
EBUS experience which is characterized by indentation of calibre of vessel with 
regular margins by close contact to the lesion and failure of CT to identify it.    
In all the cases studied no tumor-infiltration of pulmonary vessels had been 
detected. 
 
3.6.4 Infiltration of mediastinal structures 
In all cases studied no infiltration of mediastinal structures was detected. 
 
3.7 Visualization of extraluminal tissue changes causing abnormal 
bronchoscopic findings 
EBUS was helpful in explanation of the bronchoscopic findings in 22 cases (44%) 
of all cases, while in 36 pathologically verified lung cancer patients it was helpful 
in 19 cases (53%). EBUS helped in elucidating the cause of carinal widening, 
extrabronchial compression, submucosal invasion, bronchial stenosis or narrowing, 
and abnormal mucosa (Table 21). In 3 non-malignant cases, extraluminal tissue 
changes were observed, 2 of them proved to be malignant in follow up, while the 
third case proved to be chronic organized pneumonia after thoracotomy.  
                                                                                                                                       
 Table 21: EBUS help in explanation of bronchoscopic findings 
Cases N R (%) 95% CI 
All studied cases (50) 22 44 30-58.8 
Pathologically verified lung 
cancer (36) 
19 53 35.5-69.6 
 
3.8 Cases without further information provided by EBUS 
Radiology and bronchoscopy provided more data than EBUS in 10 cases out of the 
50 cases studied (20 %) and in 7 cases out of 36 pathologically verified lung cancer 
patients (19%). 
These data were as follows: 
9 lymph nodes in 50 patients (previously enumerated), 
2 peripheral lesions in 50 patients (previously enumerated). 
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3.9 EBUS-assisted TBNA of EBL 
EBUS-assisted TBNA was performed in 44 lesions in 36 out of 50 cases studied. 
The main indication of TBNA was cytological diagnosis of PBL (19), enlarged 
LNs (21), peripheral (2) and bronchial lesions (2). TBNA was performed in more 
than one location in the same patient whenever the diagnostic purpose necessitate.  
EBUS-assisted TBNA of extrabronchial lesions EBL (PBL+LNs) was diagnostic in 
36 out 40 EBL (90%). 28 were malignant EBL (70%), 8 were benign EBL (30%), 
while in 4 EBL (10%) were non-diagnostic (Table 22).     
In case number 29, EBUS assisted TBNA secured a definitive cytological diagnosis 
(squamous cell carcinoma) after previously negative pathological results obtained 
by mediastinoscopy to a left extrabronchial lesion in the aortopulmonary window. 
 
  Table 22: Cytological diagnosis of EBUS assisted TBNA of EBL 
 
EBUS-assisted 
TBNA of EBL 
 
Diagnostic 
 
Non-diagnostic 
 
N N R (%) 95% CI N R (%) 95% CI 
40 36 90 73.9-96.9 4 10 3.1-26.1 
N = number.   R = Rate.  CI = confidence interval. 
 
3.9.1 EBUS-assisted TBNA of LNs  
In 19 patients, EBUS assisted TBNA of LNs were performed in 21 enlarged 
mediastinal, hilar and intrapulmonary LNs. Of these 13 were detected by EBUS 
only and 8 by both EBUS and CT. 
Diagnosis by EBUS-assisted TBNA of LNs was achieved in 19 lymph nodes   
(90%), while in 2 LNs (10%) EBUS-assisted TBNA of LNs was non-diagnostic 
(Table 23). 12 LNs (63%) were tumor-invaded and in 7 LNs were benign (37%). 
12 of the 19 diagnosed LNs were detected by EBUS only (63%), 7 (37%)of them 
were malignant.  
 
             Table 23: Results of EBUS-assisted TBNA of LNs 
EBUS-assisted 
TBNA of LNs 
Diagnostic Non-diagnostic 
 
LNs N R (%) 95% CI N R (%) 95% CI 
21 19 90 68.3-98.7 2 10 1.23-31.7 
N = number.   R = Rate.  CI = confidence interval. 
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2 EBUS-only detected benign lymph nodes (case 1 and 39) had their histology 
confirmed later by mediastinoscopy.  
No complications were recorded from TBNA procedures. 
 
?Change of staging and therapeutic consequences: 
7 malignant LNs were additively detected by EBUS only and diagnosed by EBUS-
assisted TBNA in 5 cases (Cases No.  9, 23, 44, 47 & 50).  
The nodal descriptors (N) changed from N0 to N1, N1 to N2 and N0 to N2 in 1, 2 and 
1 case respectively. In the fifth case, there was no change in the nodal descriptors 
(N). The nodal descriptors (N) changes in the 4 cases lead to changes in patients’ 
tumor stages in 2 cases. However, this change had no therapeutic consequences on 
patients, as they were functionally inoperable.  There was no change in tumor 
descriptors (T) by addition of EBUS in the present study. 
 
3.10 Sedation 
The mean value of midazolam sedation given was 6 ± 3.5 mg. 
 
3.11 Complications and patient tolerance  
All complications encountered were either mild or moderate oxygen desaturation in 
6 and 1 respectively, mild and moderate cough (9 and 3) and 2 cases of tachycardia. 
No bleeding was recorded  (Table 24). 
 
                     Table 24: Complications of EBUS in all studied cases. 
Desaturation Cough Bleeding Tachycardia Complications 
N % N % N % N % 
Mild 6 12 9 18 0 0 2 4 
Moderate 1 2 3 6 0 0 0 0 
Aborted 
examination 
0 0 0 0 0 0 0 0 
Total 7 14 12 24 0 0 2 4 
 
A patient tolerance score was plotted based on complications encountered (Table 
25):     
1-Complete tolerance (no complications) in 33 cases (66%). 
2-Partial tolerance (mild to moderate complications) in 17 cases (34%). 
3-No tolerance (procedure aborted) were not encountered. 
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    Table 25: Patient tolerance to EBUS in all studied cases.  
Tolerance N R(%) 95% CI 
Complete tolerance 33 66 51.2-78.9 
Partial tolerance 17 34 21.1-48.8 
No tolerance 0 0  
N = number.   R = Rate.  CI = confidence interval. 
 
3.11.1 Duration of EBUS and FFB examination 
When time of EBUS and FFB were recorded (34 cases), the percentage of the 
EBUS examination from the total time of bronchoscopy was calculated as 44% 
(Table 26).  
 
                  Table 26: Duration of the procedures in 34 cases  
Duration Mean value 
FFB  (including EBUS) 34 min 
EBUS 15 min 
Percentage of EBUS duration  44% 
 
3.11.2 Instrument handling Difficulties 
 
3.11.2.1 Difficulties in the balloon sheath preparation before use 
Although the instruction manual steps for balloon sheath preparation were followed 
exactly, it was always difficult to achieve a fully inflated balloon without air 
bubbles inside. 
Also the attachment of the balloon O-ring section to the ditch section of the 
ultrasonic probe with the balloon applicator (MaJ-564) or manually was difficult. 
 
3.11.2.2 Difficulties in the balloon sheath during use 
a) Dislocation of the attachment between the balloon O-ring section to the ditch 
section of ultrasonic probe occurred twice during the present study. 
b) Perforation of the balloon occurred twice during the present study. 
 
3.11.2.3 Image artifacts 
The most commonly met artifact were in the form of: 
a) Radiating images, appearing as broken black lines from the center to the 
periphery.  
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b) Multiple repeated reflections artifacts due to the balloon echo occurred when 
there was insufficient contact between the balloon and the bronchial wall. 
c) Multiple edges between the images. 
 
3.11.2.4 US image adjusting difficulties  
Adjusting the ultrasound image is only possible in real-time mode, thus adding 
more time to the examination to adjust image quality while the balloon is 
completely inflated. Freeze-frame images cannot be adjusted. This sometimes lead 
to inadequate image picture quality.   
 
3.11.3 Orientation difficulties related to the instrument 
a) The subscreen containing the endoscopic picture was too small to see the relation 
of the ultrasound probe in the bronchus examined.  
b) The movement of the bronchoscope with the ultrasound probe is in 2 directions 
only. So in order to orient in 4 directions (medial, lateral, anterior and posterior), 
the bronchoscope with the ultrasound probe needs to be rotated in another plane 
perpendicular to the first, occasionally leading to loss of orientation.  
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3.12 Typical case demonstration 
 
Case 1: 
A 76 male patient, with a smoking history of 60-pack year was referred to our department after 
undergoing diagnostic mediastinoscopy for a mass in the aorto-pulmonary window with negative 
pathological results. Endoscopic, CT and EBUS findings are presented.  EBUS identified the 
position of the lesion in relation to the bronchial lumen, assisting in the location of transbronchial 
puncturing. Through EBUS assisted TBNA squamous cell carcinoma was diagnosed. 
 
Figure 11: An example of EBUS assisted TBNA of an extrabronchial 
lesion 
a) Endoscopically, the distal Lt. main bronchus (LMB) shows no abnormality 
 b)         c) 
 
b) The CT scan cut shows a tumor mass (TU) in the region between pulmonary artery 
anteriorly and descending aorta posteriorly. 
 
Distal LMB 
TU 
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c) EBUS in Lt. main bronchus: Antero-laterally there is an echo free area of the left 
pulmonary artery (LPA) that showed vigorous pulsation during examination, postero-
laterally there is an echo free area of the descending aorta (DAO), in-between there is a 
hypoechogenic irregular area suspicious of the tumor mass (TU). 
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Case 2: 
64 year male non-smoker patient, presented with a space occupying lesion in the Rt. middle 
mediastium. Endoscopic, CT and EBUS findings are presented.   
 
Figure 12: An example of EBUS help in explanation of bronchoscopic 
findings  and an additive LN detected by EBUS only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
a)       b) 
 
a) Rt main bronchus (RMB) endoscopically without abnormality.  
b) Dorsal wall of bronchus intermedius (BI) with extraluminal compression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)       d) 
c) CT scan cut shows pulmonary artery (PA) anterior to bronchus intermedius and   
    a tumor mass dorsally. 
d) EBUS in bronchus intermedius explained the endoscopic appearance of  
    extraluminal compression by on site identifying an underlying hypoechogenic    
RMB 
RULB
BI 
PA 
TU 
PA 
TU 
B.I.  
RMB 
RULB
BI 
PA 
TU 
PA 
TU 
B.I.  
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    tumor mass (TU), additionally defining the exact relation of lesion to pulmonary artery  
 (PA),   which appears as an echo free area anteriorly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e)              f) 
 
e) CT scan cut shows pulmonary artery (PA) anterior to Rt. main bronchus, with    
    no evidence of enlarged LN in this area (circle). 
 f) EBUS in Rt. main bronchus (RMB), echo free area of the pulmonary artery (PA)   
    anterior and azygos vein (AZ) posterior. An additional enlarged Rt. hilar   
    LN (#10R) measuring 12 x 10 mm is seen laterally, changing the patient’s nodal   
    stage after TBNA.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PA RMB 
PA 
LN 
AZ 
PA RMB 
PA 
LN 
AZ 
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Case 3: 
76 year male patient, with a well known history of COPD and a smoking history of 80 pack 
years, presented with a rounded lung shadow in Rt middle radiological lung zone. Chest x-ray, 
endoscopic, CT and EBUS findings are presented.   
 
Figure 13: An example of a peripheral lung lesion  
 a)         b) 
 
a) Chest x-ray postro-anterior view showing a rounded lung shadow in Rt middle lung  
     field. 
b) CT scan cut showing the same peripheral shadow in the region of the medial  
    segment of the middle lobe. 
c)             c) 
 
c) Endoscopic view showing no abnormality. 
    (RB5 = medial segment of Rt middle lobe, RB5a and RB5b are dorsal and ventral  
    subsegments. RB5a(ii) is a further dorsal subdivision. RB4 = lateral segment of Rt      
    middle lobe.) 
d) Endoscopic view while advancing the EBUS probe. 
RB5a 
RB4 RB4 
RB5 RB5b RB5a 
RB4 RB4 
RB5 
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e) EBUS in RB5a: Showing hypoechogenic irregular area suggestive of tumor   
    mass (TU), and an echo free area of a pulmonary vein (PV), which was identified  
    by its weak sluggish pulsations during motion.  
f)  EBUS in RB5a ii: after advancing the probe more distally, showing hypoechogenic    
    irregular area of suggestive tumor (TU) measuring 15.7 x 9.1 mm, with an echo   
    free area of a pulmonary vein (PV). 
    Through TBNA of the peripheral lesion squamous cell carcinoma was diagnosed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PV PV 
TU 
PV 
TU 
PV 
a ii 
TU 
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Case 4:  
A 70 year old male patient, with a smoking history of 60-pack years and a well known history of 
chronic bronchitis, presented with a suspicious shadow in the Lt upper radiological lung zone.     . 
Endoscopic, CT and EBUS findings are presented.   
 
Figure 14: An example of a peripheral lung lesion with bronchial wall 
invasion, EBUS definition of depth of invasion and explanation of 
bronchoscopic findings. 
 
 
 
 
 
 
 
 
 
 
 
 
   a) 
a) Endoscopically the apico-posterior segment bronchus of Lt upper lobe (LB1-2) is   
    narrowed with mucosal redness and hypervascularization. 
 
 b)              c) 
 
b) CT scan cut shows a tumor mass  in the apico-posterior segment of Lt. upper lobe 
    (LB 1-  2). 
c) EBUS in the apico-posterior segment bronchus of Lt upper lobe (LB1-2) explains the    
    cause of endoscopic appearance by identifying the underlying tumor mass (TU). This    
LB1-2 
TU 
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    is an example of invasion of the bronchial wall from outside, invasion is up to the  
    bronchial cartilage with intact mucosa and submucosa (arrow).   
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4. Discussion 
4.1 Lung cancer status 
Lung cancer is the most common cause of cancer death for both men and women in 
the United States, and it is a growing worldwide problem, especially in developing 
countries, killing over 85% of those it afflicts within five years. The dimensions are 
of epidemic proportion and reflect the general failure of conventional diagnosis and 
treatment (13, 55, 74). In Germany 42,000 newly diagnosed patients are recorded 
annually, of whom only 6,000 are expected to survive five years (56). 
In the past, there were few good options for the detection, prevention, or treatment 
of lung cancer. This led to considerable pessimism regarding the care of patients 
with the disease. In the recent past, however, there have been many advances in 
understanding the biology, early detection, staging, prevention, and treatment of 
lung cancer, which together with improved nursing and home care, are bringing 
about a reassessment of the nihilistic attitude of physicians toward lung cancer 
patients (13). 
 
4.2 Inefficiency of conventional methods 
The art of bronchoscopy has progressed at a rapid pace over the last 30 years. From 
its humble beginnings as a mere curiosity, the bronchoscope has become an 
essential component in the struggle against lung cancer (63). 
Improvements in flexible bronchoscopic optics and image acquisition technology, 
as well as in the tissue sampling capabilities of the procedure, have expanded its 
applications, resulting in an overall diagnostic yield for NSCLC and SCLC in 
excess of 95% for visible lesions (1, 76). 
At the same time limitations of bronchoscopy are well recognized. The view of the 
bronchoscopist is limited to the lumen and the internal surface of the airways (9). 
Many pathological processes of airways involve the submucosal and the 
peribronchial structures including mural and extramural tumors and metastatic 
enlarged lymph nodes. Some of these processes are suspected from indirect signs 
such as discoloration and swelling of the mucosa, pathological vascularization, 
leveling of the cartilage relief or impression, displacement or destruction of the 
airway wall, while others can not be suspected as they show no endoscopic signs 
(9, 49). Thus, the diagnostic yield tends to be much lower in submucosal and 
peribronchial diseases than for the exophytic lesions (49).   
The inability to directly visualize peripheral lesions together with other factors 
contribute to the lower diagnostic rate of peripheral masses at bronchoscopy (18). 
In bronchoscopic evaluation of tracheobronchial wall infiltration by cancer of the 
esophagus, macroscopic abnormalities of airway invasion are infrequently seen, 
sole bronchoscopic inspection is not reliable. Extensive bronchoscopic sampling 
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may be helpful (64). However in the absence of macroscopic signs, they are blind 
procedures.  
 
The success of endobronchial therapies such photodynamic therapy is strongly 
influenced by the depth of the infiltration of the tumor into bronchial wall or 
extrabronchial invasion, information never reliably obtained by endoscopic views 
and even random biopsies alone (50).   
Therefore there is an essential need to overcome these limitations through 
extending the view of the bronchoscopist beyond the tracheobronchial lumen (32).  
 
Imaging modalities play an integral role in diagnosing, staging, and following 
patients with lung cancer (60). The role in the diagnosis is focused on 
preprocedural planning, aiding in establishing an appropriate approach for 
bronchoscopic biopsy (79). 
Aided by standard chest radiography, CT and fluoroscopy during bronchoscopy, it 
is possible to further localize peripheral lesions, extraluminal tumor or lymph nodes 
that are amenable to transbronchial biopsy, but in spite of radiographic guidance 
and visible deformity, the precise locations of peripheral lesions, extraluminal 
masses or lymph nodes viewed through the bronchoscope may not be obvious. It is 
also usually not possible to identify major pulmonary and mediastinal blood vessels 
(27). This is attributed to the fact that CT or magnetic resonance imaging can help 
with the prebronchoscopic planning, but on application of cross-sectional imaging 
to the actual bronchoscopic procedure it is limited. This is also evident in new 
techniques such as virtual bronchoscopy, which may help the bronchoscopist with 
prebronchoscopic planning, but up till now no applied technique has effectively 
linked the bronchoscope with the CT images to aid the procedure itself (77). 
In addition Solomon and his colleagues (77) speculated that the limitation 
encountered from C-arm fluoroscopic guidance of peripheral lesion is due to the 
fact that the lesion lies in three-dimensional space while the fluoroscopy image at 
any time is two-dimensional only (even though this limitation can be overcome by 
rotational fluoroscopy). Solomon’s observations reinforces the essential need to 
extend the bronchoscopic view beyond the lumen during the bronchoscopic 
procedure. 
 
Staging is critical for treatment of lung cancer. Computed tomography is one of the 
most commonly performed imaging modalities in assessment of lung cancer, 
evaluating local extent, mediastinal invasion and in staging of mediastinal lymph 
nodes. Despite its safety and utility, a number of limitations to use CT as a sole 
staging test exist. CT has its limitation in evaluating tracheobronchial wall structure 
and thus cannot reveal the exact depth of the tumor invasion (82). Similarly the 
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sensitivity of CT in the detection of invasion of vital mediastinal structures e.g. 
great vessels, trachea and esophagus is low, with reports of sensitivity in the ranges 
of 60-75% (1). The CT ability to show lymph node enlargement clearly is not 
sufficient, due to the movement and the partial volume effect of the pulmonary 
artery and vein, aortic arch and the left atrium (20). Thus not all mediastinal nodes 
can be detected by CT (17). The short-axis diameter greater than 1 cm criteria used 
as an indicator of pathologic enlargement is a nonspecific criterion for malignancy, 
as the incidence of metastases in normal sized nodes (<1 cm) on CT were 21% in 
patients with non small cell lung cancer who underwent thoracotomy in a recent 
study (2, 60).  
Another study (25), comparing the imaging TNM [(i)TNM] determined by CT 
findings and pathological TNM [pTNM] determined by pathological examination 
of the resected tumors and lymph nodes, in  the staging of bronchogenic carcinoma, 
reported the following: the agreement between (i)TNM and pTNM was only 
35.1%. The primary tumor (T) was correctly staged in 54.1%, over-staged in 27.0% 
and under-staged in 18.9% of the patients. Sensitivity and specificity of CT 
regarding hilar and mediastinal lymph node staging were 48.3 and 53.3%, the nodal 
(N) factor was correctly determined by CT scan in 35.1%, over-staged in 44.6%, 
and under-staged in 20.3% of the patients. Thus even with present-day CT scanners 
(i) TNM provides no accurate staging of bronchogenic carcinoma. 
 
Even as invasive procedures as mediastinoscopy, considered the ‘‘gold standard’’ 
of preoperative mediastinal evaluation, cannot evaluate all mediastinal 
compartments or lymph node groups, and a significant percentage (up to 33%) of 
patients with bronchogenic carcinoma who have a negative mediastinoscopy prove 
to have mediastinal nodal metastases at surgery (28, 78).  
The use of TBNA can eliminate the need for mediastinoscopy for evaluating right 
paratracheal, mediastinotomy (especially for left paratracheal and 
aorticopulomonary window lesions) and open thoracotomy (in particular for 
posterior subcarinal lesions). In the literature TBNA diagnostic results can be 
expected in between 50% to 80%, clearly there is room for improvement. 
Furthermore, not all investigators have been able to consistently reproduce these 
results and it remains underutilized (53).       
 
For these reasons, it is necessary to improve the diagnostic tools for bronchoscopic 
staging of the mediastinum, through new procedures. 
 
4.3 Endosonography 
Endosonography has been proven to be superior in imaging beyond the luminal 
surface, providing information about the exact location of masses as well as such 
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normal structures as arteries, veins, and lymph nodes.  It is well established in other 
fields of medicine (88, 91). This is especially true for gastrointestinal endoscopy, 
where EUS has its place in staging of carcinoma of the esophagus, cardia and 
colorectum exerting decisive influences on therapeutic decisions (3, 40, 83). 
Recent trials using EUS for nodal staging of lung cancer were hindered by inability 
to assess N3 disease in the anterior mediastinal compartment due to interposition of 
the trachea (29). 
After overcoming technical problems EBUS became available for clinical practice 
and early reports are encouraging (6, 27, 79).  
 
In the light of previously enumerated limitations in conventional diagnostic 
methods of lung cancer, the use of EBUS was evaluated to assess its use in 
overcoming these limitations.  
 
4.4 The present study as it relates to reports in literature 
In a prospective study involving 50 patients with suspected lung cancer, two 
hypotheses were tested: EBUS provides valuable additional information for 
assessment of lung cancer compared to bronchoscopy and CT; and the use of 
EBUS in bronchoscopy under topical anesthesia is practicable and applicable in 
spite of some prolongation in the examination time. 
Fifty consecutive patients with suspected lung cancer undergoing diagnostic and/or 
staging fiberoptic bronchoscopy under topical anesthesia were recruited.  All the 
patients without contraindications for conventional fiberoptic bronchoscopy had a 
clinical history together with shadow(s) or mediastinal adenopathy in computed 
chest tomography  ± chest x-ray suspicious of lung cancer. These subjects provided 
the basis for EBUS addition to the usual routine bronchoscopic workup performed 
for assessment of lung cancer.  
 
4.4.1 EBUS examination anesthesia, sedation, application sites and duration 
In contrast to other reports applying EBUS in general anesthesia (8, 19, 36), in this 
study it was applied under topical as it is customary in routine, ambulatory 
endoscopy. 
In the present study, prebronchoscopic patient preparation and topical anesthesia 
were no different to the usually applied methods in our bronchology unit. In 
addition to 100 mg prednisolone given intravenously 90 minutes before 
bronchoscopy, 2.5 mg Salbutamoul solution + 0.25 mg Ipratropium bromide 
solution were added to the lidocaine 4% solution inhalation in COPD patients to 
decrease cough and bronchospasm. Cautiously titrated i.v. midazolam sedation was 
given under continuous oxygen supplement and pulse-oxymetric monitoring 
throughout the procedure. 
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The mean value of midazolam sedation given was 6 ± 3.5 mg; no complications 
related to midazolam sedation were recorded and no benzodiazepine antagonist was 
needed. 
The number of EBUS applications in different locations was 114 in 50 patients. No 
difficulty in reaching all desired locations with the ultrasound probe was recorded 
(Table 8, Fig. 7).  
The positions of EBUS applications were selected on the basis of the radiological 
and/or endoscopic findings, surveying these regions until the lesion was reached, 
under consideration of the standard positions stated in the literature (7). 
A similar selection concept based on radiological and/or endoscopic findings prior 
to EBUS examination were reported by Goldberg et al. (27) and Steiner et al. (79). 
The mean duration of EBUS was 15 minutes, it constituted 44% of bronchoscopy 
time in the present study (Table 26). In comparison to other studies under topical 
anesthesia, EBUS examinations ranged between 5-15 minutes and constituted 
between 20-60% of bronchoscopy time (19, 69), while under general anesthesia 
EBUS examinations ranged between 3.1-14.4 minutes (36). The added time in the 
present study is expected with spontaneously breathing patient under conscious 
sedation with strong respiratory movements, coughing, and clearing of secretions 
which lead to delay localization and acquisition of good documentation.  In 
addition to, EBUS application in more than one site in each patient and cautious 
examination to achieve the best patient tolerance during the examination.  
 
4.4.2 EBUS detection of anatomical-pathological structures, central and  
         peripheral lesions  
Different anatomical-pathological structures could be identified by EBUS including 
blood vessels, esophagus, normal lung parenchyma, lymph nodes and tumors. Each 
has a peculiar sonographic pattern, which were similar to previous EBUS studies 
(27, 32, 79). 
Some difficulties were encountered in the differentiation between arteries and veins 
especially in the right and left lower lobes even after a trial to synchronize the 
arterial pulsations with pulse-oxymetry. This can be attributed to the wide 
anatomical variation in the positions and the numerous adjacent small caliber 
branches of the pulmonary arteries and veins in right and left lower lobes, with the 
possibilities of transmitted pulsations to veins. Similar difficulties were reported by 
Herth and Becker (32) and Scherer et al. (69), even after application of echo 
contrast medium it was difficult (32).   
In one case, the detailed internal echo structure of a lymph node revealed a central 
hyperechogenicity lying against the hypoechoic background representing fat 
surrounding the nodal hilum. This picture represents a typical sonographic pattern 
of normal nodal architecture previously demonstrated in other areas of the body 
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and in peribronchial lymph nodes (27, 30, 79). In another case the lymph nodes 
appeared as hypodense irregular structures in the usual anatomical site, it was 
thought that this pattern might occur when the node metastases had invaded 
through the node capsule (extra-nodal metastases) (61).  
A search for a sonographic echo-pattern or suspicious size of the enlarged LNs 
suggestive of malignant infiltration or benign enlargement was non-productive, as 
the gold standard for involvement of LNs by metastases is cyto-histological 
evidence. Becker and Herth in an invitro study were not able to find reliable 
sonographic signs for malignant infiltration (32).  
 
The suspected lesions were classified into central, peripheral or combined lesions 
based on combined FFB and CT findings (Table 9). In all cases, studied EBUS 
detected 34/34 central lesions (100%), 12/14 peripheral lesions (86 %), and 2/2 
with combined central and peripheral lesions (100%) (Table 10).  
In the 36 cases with pathologically verified lung cancer, EBUS detected all the 
cases with central lesions i.e. 23/23 (100%), 11/12 peripheral lesions (92%) and the 
case with combined central and peripheral lesions (100%). Thus, EBUS only failed 
in detecting one peripheral lesion (3%). EBUS was highly efficient in detecting all 
tumors, with equal detecting capability for central and peripheral tumor sites (Table 
11& 12).  
Several studies showed nearly similar results to the present study, taking in 
consideration the differences in systems used for EBUS applications.  
Hürter and Hanrath (39), in their early experience with EBUS application in 
patients with lung cancer, could identify 69/74 of the central lesions (93%) and 
19/26 of the peripheral lesions (73%) by EBUS. However, they used 20 MHz 
ultrasound transducer-containing catheter without a balloon sheath, different from 
the method applied in the present study, and used a similar definition of central and 
peripheral lesions, but based on endoscopy only.  
Goldberg et al. (27), in a series of 25 patients with known or suspected lung cancer, 
using 12.5 or 20 MHz US probes as that used by Hürter and Hanrath (39), applied 
the same definition of central and peripheral lesions adopted in the present work. 
They could identify 19/19 of the central lesions (100%), 4/6 of the peripheral 
lesions (67%) by EBUS, because of the difficulty to maintain adequate contact with 
the bronchus, 2 cases could not be detected. 
Steiner et al. (79), used the same system and frequency applied by Goldberg et al., 
(27), but tried to eliminate the air around the transducer by injecting sterile water in 
the chamber between the catheter and the transducer. They could identify 15/15 of 
the central lesions (100%) by EBUS, 20/22 of the peripheral lesions (91%) and all 
the cases with combined central and peripheral lesions 7/7 (100%) in 44 cases with 
clinical and radiological evidence of central and peripheral thoracic masses. 
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4.4.3 Additional information provided by EBUS 
In all areas examined by EBUS, CT and FFB, agreement about the main features of 
the primary disease processes was achieved, but the main interest was on the 
additional data EBUS could provide in addition, in the form of further lymph 
nodes, depth of tumor invasion, blood vessel impression or infiltration. Also it 
helps in explanation of the bronchoscopic findings and its assistance of TBNA.                                        
 
4.4.3.1 Lymph nodes 
The lymph nodes studied were classified into three groups according to the method 
of detection: LNs detected by CT and EBUS, by EBUS only, or by CT only. 
Characterizing a lesion as a lymph node takes into account similar sonographic 
patterns of lymph nodes in other areas of the body (30), and appearance of 
cytologically verified nodes from previous EBUS experience. 
In the search for draining lymph nodes proximal to the primary lesions, EBUS 
detected nodes not present in CT prior to bronchoscopic-EBUS procedure. Thus, 
EBUS may identify additional proximal LNs, which might be helpful in staging. 
The total lymph nodes detected by EBUS in pathologically verified lung cancer 
patients, were variably distributed, including mediastinal, hilar and intrapulmonary 
LNs groups. Their position in relationship to the bronchial lumen, depicting shape, 
border and size, longitudinal and cross diameter, delineating surrounding structures 
as pulmonary and mediastinal vessels was a help in performing TBNA. The outer 
border of LN were sometimes beyond the EBUS range, making it difficult to 
measure the exact cross diameters in all cases, but when measured it ranged 
between 0.4 to 2.5 cm. Similar reports contain fine sonographic images of a variety 
of LN groups, and LN size as small as 3 mm (11, 27, 41, 70, 75, 79).  
Sagawa and his coworkers (65) compared the diagnostic value of CT with that of 
transtracheobronchial ultrasonography (TUS) in the evaluation of mediastinal 
lymphadenopathy in 5 patients with resectable lung cancer. They found that the 
sizes of LN measured by TUS were similar to or slightly smaller than the sizes as 
measured by CT. Hilar and right paratracheal LN were clearly observed with TUS, 
but were sometimes unclear with CT.  
EUS also proved to be superior to CT in the detection of mediastinal lymph nodes 
and it was possible to visualize nodes as small as 5 mm (29).   
In addition, not all mediastinal nodes could be detected by CT (17, 20) and that 
imaging TNM (using CT) was congruent with pathological TNM, as regarding the 
nodal (N) factor in only 35.1%, of the patients (25). All this supports the ability of 
EBUS to identify additional LNs and to clarify and delineate masses and LN better 
than CT in the present study.       
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In the pathologically verified lung cancer patients, seven LNs had been detected by 
CT only and not by EBUS. In 4 lower paratracheal LN, failure of detection could 
be attributed to impaired patient tolerance to the procedure in the trachea, and to 
incomplete coupling between the balloon sheath and tracheal lumen. However, in 
the last three examinations of the trachea, detection of lower paratracheal LNs was 
successful. This might be attributed to a different examination technique. By 
pushing the US probe towards the suspected site of lower paratracheal LN on the 
tracheal wall before the balloon inflation, so an image can rapidly be captured.     
Scherer et al. (70), reported similar difficulties during examination of paratracheal 
LN, where full inflation of balloon in the trachea for achievement of good coupling 
was not tolerated by patients. The tracheal examination had to be terminated 
prematurely in 34%.   
Lack of patient tolerance was responsible for failure of depicting one subcarinal 
LN, while in one Rt hilar LN the EBUS image itself was inconclusive. The para-
aortic LNs could not be detected, as they are beyond EBUS detection range. Wang 
(90) stated that these LNs are beyond reach of TBNA as well. When involved by 
lung cancer, they are often associated with involvement of subaortic or left hilar 
LN, then they can be reached by EBUS assisted TBNA easily.  
 
4.4.3.2 Depth of tumor invasion  
The most acceptable available definition for identifying the laminar structure of the 
tracheobronchial wall described by Kurimoto et al. (42), has been used in the 
present study (Table 1). Frequently the multi-layers of the normal bronchial wall 
are not easily identifiable. The third marginal layer (inner-side border of cartilage 
or cartilage-endochondrium) and the fourth layer (bronchial cartilage) appear as 
hyperechogenic, hypoechogenic layers respectively, near the middle part of the 
bronchial wall and this is a helpful landmark for identifying the remaining layers of 
bronchial wall. The depth of tumor invasion could be identified by its relation to 
the bronchial cartilage, which could be detected and pointed out clearly. 
In the 36 pathologically verified lung cancer patients, tumor invasion of the 
bronchial wall had been identified as an additional information provided by EBUS 
over CT and FFB in 21 cases. Invasion beyond the adventitia was documented in 
13 cases, up to the adventitia in one case associated with lymph node invading the 
bronchial wall, invasion of cartilage in 3 cases, and tumor invading from outside 
the bronchial wall in 4 cases. 
 
All these areas were confirmed to be malignant histologically through 
bronchoscopic biopsy (forceps or needle), this however could not confirm the exact 
depth of invasion. In addition, all the cases diagnosed were non-operable, so the 
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correlation between the images of the depth of invasion obtained by EBUS and 
histology could not be performed. 
It has been reported previously that high frequency ultrasound endoscopy proved to 
be superior to CT and MRI in demonstrating detailed structures of wall of various 
tubular organs and in evaluation of the depth of tumor invasion of the wall (16). In 
both gastrointestinal and respiratory systems, the accuracy of evaluation of the 
tumor invasion were much higher than CT, with EUS it was 89%, where as by CT 
it was only 59% (84), while for EBUS it was 94%, and for CT it was only 51% 
(34).    
The definition of the detailed layers of the normal bronchial wall and the detailed 
depth of tumor invasion by EBUS varies between experimental and clinical studies.  
Under favorable conditions in experimental studies, as needle-puncture experiment 
preformed by Kurimoto et al. (42), the details of laminar structure of normal 
tracheobronchial wall could be easily identified on specimens from human tracheas 
and bronchi, demonstrating the histological anatomical structures corresponding to 
each sonographic alteration. In addition, the detailed depth of tumor invasion by 
EBUS could be classified into four levels: submucosa, cartilage, adventitia and 
beyond adventitia, from resected lung cancer specimens. 
Recently and in agreement to the present study, Miyazu et al. 2001 (50), using the 
same sonographic definition of the laminar structure of the tracheobronchial wall 
and 20 MHz ultrasound probe, demonstrated that it was difficult to detect all the 
layers of normal bronchial wall and consequently the four levels of the depth of 
tumor invasion by EBUS in a clinical study. As the cartilage layer was clearly more 
evident than any other layer in agreement with other EBUS studies (42, 82) the 
depth of tumor invasion could be categorized into two levels, whether the cartilage 
is involved or not. This categorization seemed practicable when applied to 3 
resectable invasive lung cancers (cartilage involved). The histopathological 
findings after resection were congruent with the EBUS evaluation. In two other 
patients with early lung caner (cartilage not involved) a decision for photodynamic 
therapy was made. EBUS results determined the choice of therapy.  
EBUS has its clinical implication on centrally located early lung cancer staging and 
treatment strategy. In conjunction with new methods as combined automated 
sputum cytometry and cytology for detection (54, 56), autofluorescence 
bronchoscopy for localizing and delineating tumor margins (56, 81), EBUS can 
determine depth of tumor invasion and enlargement of regional lymph nodes (42, 
36). The decision as to which therapeutic modality (surgical or endobronchial) 
should be applied for cure (81, 50) may depend on whether the cartilage is involved 
or not (50).      
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In the present study, tumor invading from outside the bronchial wall had been 
described when most of the sonographic pattern of tumor (hypoechoic) was lying 
outside the bronchial wall and involved wall structures. (i.e. extramural-intramural 
invasion), this pattern of invasion which was not described before by Kurimoto et 
al. (42). It is only of importance in surgical resection decision making of 
mediastinal tumors, paratracheal tumors, thyroid tumors and metastatic lymph 
nodes.  If the adventitia is not involved it can be assumed that the patient is 
operable. Herth and Becker 2001(34) had the same concept in central tumor 
growth, in which EBUS allowed the differentiation between tumor invasion and 
impression with much higher accuracy (94%) than CT (51%) and added that 
patients judged radiologically initially as inoperable tumor, could be operated after 
EBUS evaluation. In a recent study in 2001(85), EBUS was potentially more useful 
in diagnosing tracheal invasion by thyroid cancer, compared with conventional CT 
and/or MRI. 
In the new TNM staging of lung cancer 1997 (52), superficial tumors with their 
invasive component limited to the bronchial wall are classified T1 even if they are 
in the main bronchus. Defining this entity non-invasively is possible through EBUS 
imaging of the bronchial wall only.  
 
Kurimoto et al., 1999 (42) added information on the limitations of the EBUS 
estimation of tumor invasion at present time: it can be difficult due to poor 
definition on the luminal side of the cartilage at 20 MHz, attenuation by the 
balloon, difficult visualization at bronchial spurs and the need for a thick flexible 
bronchoscope because of the balloon sheath. In addition, they considered several 
measures to deal with these problems as examination at a higher frequency for 
example, 30 MHz, improvement of balloon quality, diagnosis by making 
longitudinal slices of the bronchi with a three-dimensional ultrasound system and 
making the probe thinner. 
 
4.4.3.3 Infiltration or impression of mediastinal structures 
Impression of pulmonary arteries by enlarged lymph nodes were identified by 
EBUS in 2 cases, in addition infiltration of mediastinal vessels or structures was 
excluded by EBUS in all areas examined.  
Herth and Becker (32, 34), could either diagnose or exclude infiltration or 
impression of mediastinal structures as aorta, vena cava, esophagus or pulmonary 
artery which frequently proved to be difficult by radiological methods, and was an 
important point in the preoperative staging process.  
EBUS played an important role in preoperative decision-making. In a case of 
esophageal cancer (case 36), this meant the exclusion of tumor infiltration into the 
trachea, as there was a clear sonographic demarcation between the esophageal 
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tumor and the tracheal adventitia. This is of value in both tumors originating from 
the esophagus with possible infiltration of the tracheobronchial wall or tumors 
originating from the distal trachea or left main bronchus with possible infiltration 
of esophagus. In the previous two situations, EBUS proved to be superior to 
radiology (34, 82). 
 
Summing up the previously discussed additional data (lymph nodes, depth of 
bronchial wall invasion, blood vessel infiltration or impression) in the 
pathologically verified lung cancer cases, EBUS provided additional data to FFB 
and CT in 25 patients (69%), while FFB and CT were superior to EBUS in 7 
patients (19%). Statistically the additional data provided by EBUS more than FFB 
and CT were highly significant as compared to the data that by FFB and CT 
provided more than EBUS (Table 13).  
 
4.4.4 Explanation of abnormal bronchoscopic findings 
EBUS was also helpful in explanation of the bronchoscopic findings in 19 cases out 
of 36 pathologically verified lung cancer patients (53%) (Table 21). EBUS helped 
in elucidating the cause of carinal widening, extrabronchial compression, 
submucosal invasion, bronchial stenosis or narrowing, and abnormal mucosa. 
EBUS could identify underlying enlarged LNs, extrabronchial tumor, intramural 
tumors related to these bronchoscopic findings.  EBUS thus provides immediate 
information, even in absence of CT about the underlying cause of indirect 
bronchoscopic tumor signs during bronchoscopy, delineating surrounding 
structures e.g. blood vessels. An important feature is the identification of the 
relationship between the lesion and the bronchial lumen thus aiding TBNA.  
 
4.4.5 EBUS-assisted TBNA 
EBUS-assisted TBNA of EBL had diagnostic rate of 90%, of which 70% were 
malignant and 30% were benign. There were no complications recorded related to 
TBNA (Table 22). Early previous experience with standard TBNA in the study unit 
had a diagnostic rate 33% (37), thus EBUS assistance improved the diagnostic 
yield. However Falcone et al., (18) gave lower diagnostic rates for EBUS-assisted 
TBNA 60% (21 cases were diagnostic out of 35), but this could be more related to 
the trial in small diameter LNs. 
EBUS-assisted TBNA of lower paratracheal, subcarinal, subaortic, hilar, and 
intrapulmonary LN had been performed aiming to obtain cytological diagnosis of 
enlarged LNs, even in the technically more difficult sites as aortopulmonary area 
due to its proximity to major vessels (90). Subaortic LNs could be easily and safely 
sampled after EBUS localization.  
In all cases of TBNA, technical precautions were taken to abolish any risk of 
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contamination of samples by bronchial secretions and debris that is characterized 
by scattered, rare neoplastic cells against a background of bronchial secretions (75). 
In addition, careful sampling was adhered to in cases of close proximity of the 
primary tumor to punctured LN. Thus, the incidence of false positive aspirate is 
likewise rare, and no necessary further surgical confirmation is needed (14, 67, 68)  
An adequate cytological specimen is characterized by absent or a paucity of 
columnar epithelial cells and a large number of lymphocytes and malignant cells to 
confirm the diagnosis of malignancy, while absence of lymphocytes in the 
specimen is considered inadequate sample (49, 68). 
EBUS-assisted TBNA of LNs was diagnostic in 90 %, of which 63% were 
malignant and 37% were benign, in these 12 LNs were detected by EBUS only 
(63%), in which 7 (37%) of them were malignant (Table 23).  
Herth and Becker reported that EBUS-assisted TBNA of LNs had improved the 
yield of TBNA, a diagnostic yield of 82% had been reached, in which 64% were 
malignant and 36% were benign and added that in further experience the yield was 
close to 90% (35). An initial study in 1996 (75) comparing US-directed TBNA and 
standard TBNA of mediastinal adenopathy, found USTBNA exhibits a similarly 
high diagnostic yield (84%) to standard TBNA in setting of rapid on-site 
cytopathology evaluation. USTBNA reduced the number of aspirates and provided 
easier biopsy approach in paratracheal LN in particular while sampling smaller 
nodes. The authors attributed these results to their very high sensitivity for standard 
TBNA, to the presence of on-site cytopathology and technical difficulties imposed 
by using initial 12.5 or 20 MHz US catheters intended for intravascular use (75). 
However, only subcarinal and paratracheal LNs were included and difficult risky 
areas like aortopulmonary window (subaortic LNs) were not included.  
A recent study in 2001 (24) aimed to demonstrate the usefulness of CT 
fluoroscopic guidance in improvement the yield of TBNA of subcarinal and 
precarinal LNs in whom previous standard TBNA was non-diagnostic. A high 
diagnostic yield 87.5% had been reached in which 75% were malignant and 25% 
were benign. However there was a need for an attending radiologist, cytologist, and 
the procedure had been performed within a regular interventional CT time slot of 
one hour in CT suite, this in addition to the relatively high risk of radiation 
exposure. 
In the benign group of the previous study (24), 6 out of 7 patients had lymphocytes 
only in the specimen. Follow-up showed only one of these 6 patients to have 
malignancy.  Similarly in the present study, in the benign group, 5 out of 7 patients 
had lymphocytes only in specimen (lymphocytic hyperplasia of LNs), 2 of them 
undergone mediastinoscopy which confirmed the cytological diagnosis of EBUS 
assisted TBNA, while the other 3 were followed up with no evidence of 
malignancy in period more than 6 months. The presence of 5 lymphocytic 
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hyperplasia of LNs may be attributed to geographical predominance of anthracosis 
and / or silicosis in the study region. 
 
4.4.6 Change of staging and therapeutic consequences: 
EBUS was helpful in local nodal staging. EBUS-assistance to the conventional 
TBNA technique could successfully change nodal descriptors (N) in 4 cases. 
However, there was no change in tumor descriptors (T) by addition of EBUS as 
there was no detection of infiltration of mediastinal structures or vessels as well as 
early carcinoma detection in all cases studied. 
EBUS addition to the conventional methods of staging of lung cancer lead to an 
overall change in patients cancer stage in 2 cases only out of 36 verified lung 
cancer cases, but without any subsequent therapeutic consequences, as the two 
cases were functionally inoperable. 
In a population studied with the intent to characterize otherwise difficult to reach 
lymph node localizations or radiologically ill-defined tumor margins EBUS 
addition for local staging would have better subsequent effects on the patients’ 
stage, future therapy plan and considerable cost savings from unneeded surgical 
procedures. With the data presented feasibility of EBUS-examination in local 
anesthesia with precision surpassing CT and FFB can be assumed. 
 
4.4.7 Complications and patients tolerability  
The majority of complications were mild and infrequent. These included 
desaturation 6 cases (12%), cough 9 cases (18%) and 2 sinus tachycardias (4%). 
Moderate complications were rarely observed; desaturation 1 case (1%), cough 3 
cases (6%), and no examination was aborted. No serious complications were 
encountered, and these could be considered as side effects rather than 
complications (Table 24). Occasionally repeated cough lead to desaturation leading 
to tachycardia, which is not surprising, considering the large number of EBUS 
applications (114 in 50 patients). 
Patient tolerance score was plotted based on complications encountered, complete 
tolerance in 33 cases (66%), partial tolerance in 17 cases (34%) and no examination 
abortion (Table 25).     
Initial reports applying EBUS through ultrasound transducer-containing catheter 
without a balloon sheath under topical anesthesia observed no complications in 
general. This may be related to the US probe used and also a lack of emphasis on 
complications analysis (27, 39, 79).   
An initial trial was conducted applying the Olympus probes with a balloon sheath 
using rigid bronchoscopy under general anesthesia in more than 1000 patients from 
1994- June 1996. Technical problems as the large diameter of the initial probes 
precluded the use of flexible scopes (8). However after solving the initial technical 
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problems, EBUS is still used under general anesthesia on a wide scale. In a recent 
study published in 2001 (36), documenting all patients who performed EBUS 
additionally to bronchoscopy between January and December 1999, EBUS was 
applied under general anesthesia in 603 out of 648 patients studied (93%) through 
combined rigid and flexible bronchoscopy approach and through flexible 
bronchoscopy under local anesthesia in the remaining 7%, using US probes 
identical to that used in the present study. Side effect encountered were rare 
compared to the present study, 34 patients (5%) developed desaturation and needed 
supplementary oxygen during the examination, transitory cardiac arrhythmia 
occurred only during the application of the probe in the left lower lobe bronchus, in 
18 patients (17%) patients out of 103 cases, mostly they were sinus tachycardia. 
The authors make no reference to possible complications of general anesthesia. 
Similar side effects, had been reported by Scherer et al. 1999 (69) in their initial 
experience applying EBUS under topical anesthesia using probes identical to that 
used in the present study, in which cough occurred in 15-20% of examined cases. 
Contrary to the present study coughing prevented acquisition of the desired 
information mandating premature termination in 8-12%. In 10% of examined cases 
desaturation occurred and mandated repeated deflation of the balloon to improve 
the oxygenation.  
Falcone et al. 2000 (19), describing the Italian experience of EBUS in 70 patients, 
62 under topical anesthesia and 8 cases under general anesthesia, experienced much 
better patient tolerance than the present study. In 93.6% there was complete 
tolerance, in 6.4% partial tolerance related to coughing, bleeding and hypoxia and 
the examination was never prematurely terminated in all the examined cases.  
Comparison between this study and the present study is difficult, as the criteria for 
selection of patients, use of general anesthesia, the number and the positions of 
application sites in each patient had not been discussed, also the number of the side 
effects observed in the present study was recorded by complication entity (i.e. 
several complications may be present in one patient, but recorded each as a 
separate entity). Other recent reports (50, 82), applying EBUS under topical 
anesthesia, even in the trachea (82) noted no difficulties in application but without 
giving further details. 
 
4.4.8 Instrument handling difficulties 
In evaluation of the role of this new diagnostic procedure, it is important to note 
instrument handling difficulties, with the aim of minimizing these difficulties for 
new generations of the instrument, which will be more accurate and more easily 
handled. This point had not been previously focused on in literature, which may be 
related to the short period of availability (since 2000) of the instrument in the daily 
hospital practice, and the limited number of centres, which apply this new 
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technology. The difficulties in handling as previously enumerated were in balloon 
sheath preparation before and during use, imaging artefacts, instrument adjustment 
problems and instrument orientation problems. Imaging artefacts are expected as 
with any imaging instrument, and after adequate practice with EBUS application it 
infrequently hinders the diagnostic process. The most common artefacts are 
multiple repeated reflections of the balloon echo. This can be corrected by 
providing sufficient contact between the balloon and the bronchial wall thus 
achieving good coupling. These imaging artefacts are not synchronous with the 
physiological movements, they are easily recognised, and after some time of 
accommodation, they no longer interfere with the diagnostic process. 
Orientation of mediastinum sonographic anatomy in relation to the bronchial lumen 
is the primary most difficult task in EBUS application, but improves with practice. 
Also, complex anatomy of mediastinum and unusual planes of EBUS which follow 
bronchial tree may cause some problems.  
The subscreen provided for observation of endoscopic image simultaneously with 
the ultrasound image, is too small to see the position relationship of ultrasound 
probe in the bronchus examined. This difficulty had been overcome by having two 
adjacent monitors, one for each of the endoscopic image and the ultrasound signal.  
In addition loss of the examiner orientation is one of the difficulties that is observed 
during training with EBUS, it occurs due to the need to rotate the bronchoscope 
with the probe frequently for wall approximation. A help is the following 
technique: during the examination the US probe is directly pushed into contact with 
the suspected site, then the balloon is inflated, and when the suspected lesion 
appears directly in contact with the probe, then the lesion is placed into its correct 
orientation in relation to the endoscopic image by rotating the ultrasound image 
rather than the bronchoscope. Image adjustment problems had been solved recently 
in a newly launched generation of ultrasonic processors. 
The difficulties of balloon sheath, requiring time and effort still needs technical 
solutions.  
 
In contrast to other imaging modalities, EBUS application has the following 
advantages: it is safe (although requiring high degree of endoscopic expertise), 
carries no risk of exposure to ionising radiation nor intravenous injection of 
contrast material, provides real-time images in the hands of bronchologists, with 
immediate gain of information about extraluminal structures. Subsequently 
appropriate management decision can be made in one procedure without time lag.  
 
Other innovative imaging technologies, whose exact role in clinical practice is yet 
to be defined, include virtual bronchoscopy (26, 62, 87), positron emission 
tomography (72, 80, 86) and CT fluoroscopy (24, 46). Whether -and to which 
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extent- these procedures will prove to be clinically relevant, cost-effective, and 
complementary to EBUS remains to be seen. 
 
It was shown by the data presented that EBUS application under topical anesthesia 
is a well tolerated procedure, associated with mild infrequent side effects, providing 
valuable beneficial additional information to bronchoscopy and CT in assessment 
of cases of bronchial carcinoma; further expected technical improvements will 
allow EBUS to play an important role in diagnostic and interventional 
bronchoscopy in the near future.       
 
4.5 Future EBUS aspects 
Further technical improvements for EBUS application include the following: 
Addition of a biopsy channel into a balloon-integrated bronchoscope to enable 
simultaneous sonographically guided needle biopsy (10, 79). First integrated 
systems are in the prototype stage. A new ultrasonic fiberoscope prototype is now 
available, with a rotating built-in transceducer at the tip surrounded by a balloon 
allowing a 300 degrees radial scan (19). Replacing the 20 MHz probe with a 30 
MHz ultrasound device will probably allow demonstration of a more detailed 
structure of the tracheobronchial wall (82). Prototypes are being assessed. A further 
innovation is the addition of Doppler sonography for analysis of vascularization, 
which could be helpful in the control of bronchial anastomosis after surgical 
procedures (10). Further, computerized analysis of tissue characterization could be 
useful for the detection of malignancy of early carcinoma or lymph node 
metastases.  (1, 35, 40) 
Three dimensional image, image fusion techniques and EBUS-guided therapy are 
expected future developments (57). 
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5. Summary, conclusions and recommendations 
Conventional methods used for diagnosis of lung cancer are still inadquate for objectively 
estimating the exact depth of tumor invasion to bronchial wall, nodal staging, infiltration of 
mediastinal structures and extent of early lung cancer. Endobronchial ultrasound (EBUS) was 
introduced into clinical hospital practice in 2000, as a new diagnostic procedure visualizing 
bronchial and peribronchial tumors, mediastinal lymph nodes and adjacent vascular structures, 
with the aim of assessing bronchial wall and extraluminal pathology. Since major European 
publications deal with EBUS application in general anesthesia, its use in routine bronchoscopy 
under topical anesthesia has been addressed more closely in this study. Hence the primary 
question we attempted to answer has been, is the addition of EBUS under topical anesthesia to 
bronchoscopy practicable and does it improve diagnosis in bronchial cancer beyond computer 
tomography (CT) and bronchoscopy alone? 
50 consecutive patients were recruited with suspected lung cancer (suspicious shadow(s) and / or 
mediastinal adenopathy in chest CT) undergoing diagnostic and/or staging flexible fiberoptic 
bronchoscopy. In all patients, EBUS was performed as an adjuvant to bronchoscopy using 
midazolam sedation, lidocaine mucosal anesthesia and supplemental oxygen. A 20-mega Hz 
radial mechanical ultrasound probe integrated with a balloon, connected to ultrasound unit is 
advanced through the 2.8-millimeter working channel FFB to area of interest, where the balloon 
is inflated to provide a medium for ultrasound transmission. Agreement of EBUS findings with 
FFB/ CT and cyto-histology, additional information provided by EBUS, complications, patients 
tolerability under topical anesthesia were assessed.      
Out of the 50 cases with suspected lung cancer, 36 cases were pathologically verified. In 36 lung 
cancer cases, EBUS findings coincided with those of FFB and CT in main features of the disease 
process. EBUS provided additional information in 25 cases (69%), in which 20 additive lymph 
nodes were detected, depth of tumor invasion was determined in 18 cases and compression of 
pulmonary arteries in 2 cases. In addition, it was helpful in explanation of bronchoscopic findings 
in 19 cases (53%) and exclusion of mediastinal structures infiltration. On the other hand, FFB and 
CT provided additional information in 7 cases (19%). In all studied cases, EBUS assisted 
transbronchial needle aspiration biopsy had diagnostic yield in extraluminal lesions up to 89% 
and 90% in mediastinal and intrapulmonary adenopathy. EBUS addition could change the nodal 
descriptors in 4 cases and patient stage in 2 cases, but without any subsequent therapeutic 
consequences. The complications encountered in all studied cases were either mild (6) or 
moderate (1) desaturation, mild (9) or moderate (3) cough and 2 cases of tachycardia. The 
procedure is completely tolerated by most of the patients (66%). There is an average increase in 
examination time of 15 minutes, constituting 44% of total time of bronchoscopy. 
EBUS application under topical anesthesia is a well tolerated procedure, associated with mild 
infrequent side effects, providing valuable beneficial additional information to bronchoscopy and 
CT; hence its addition can improve the diagnosis and assessment of bronchial cancer. Further 
expected technical improvements are still needed, which may allow EBUS in the near future to 
play a more important role in diagnostic and interventional bronchoscopy.  
Prospective multicentre studies are needed for critical assessment of EBUS in operable lung 
cancer patients, correlating EBUS image findings with postoperative anatomical and pathological 
findings in same areas examined. A more applicable definition of depth of tumor invasion, the 
use of 30 MHz probes, the use of double lumen bronchoscopy, the cost effectiveness of 
procedure and the role of EBUS in peripheral lesions are recommended to be further studied. The 
sound indications of this new technology need to be settled, in the diagnostic investigation path 
of lung cancer. 
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